vector

Vectors expressing IL-10 specifically in microglia offer a controlled and effective treatment for Parkinson's disease, addressing the inflammatory component and minimizing side effects, thereby halting disease progression without harming dopaminergic neurons.

WO2024236193A1PCT designated stage expired Publication Date: 2024-11-21OSPEDALE SAN RAFFAELE SRL +1
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
PCT/EP2024/063802
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-17
Filing Date
2024-05-17
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

Current treatments for Parkinson's disease primarily focus on symptom management rather than addressing the underlying neurodegeneration, and existing therapies have limitations such as motor and non-motor side effects, and the need for therapies that can treat or halt the progression of the disease remains unmet.

Method used

Development of vectors, such as lentiviral vectors, for expressing IL-10 specifically in microglia to target the inflammatory component of Parkinson's disease, using miRNA detargeting methodology to ensure safe and controlled expression, and an inducible system responsive to inflammatory cues to minimize side effects.

Benefits of technology

The approach achieves therapeutic levels of IL-10 in the brain, reducing inflammation without harming dopaminergic neurons, providing a controlled and effective treatment for Parkinson's disease progression while avoiding common side effects like anaemia and immune suppression.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000059_0001
    Figure IMGF000059_0001
  • Figure 00000078_0000
    Figure 00000078_0000
  • Figure 00000079_0000
    Figure 00000079_0000
Patent Text Reader

Abstract

A vector for central nervous system (CNS)-specific expression, wherein the vector comprises a transgene encoding interleukin 10 (IL-10), and wherein the transgene is operably linked to one or more expression control sequence.
Need to check novelty before this filing date? Find Prior Art

Description

[0001]VECTOR FIELD OF THE INVENTION The present invention relates to vectors for central nervous system (CNS)-specific expression, particularly microglia-specific expression. The invention also relates to cells and pharmaceutical compositions comprising the vector and their use in therapy, including treatment or prevention of Parkinson’s disease. BACKGROUND TO THE INVENTION Parkinson's disease (PD), a neurological disorder, affects about 1% of people over 60 and it is characterised by the gradual decrease of dopaminergic neurons in the substantia nigra pars compacta (SNpc), which results in the emergence of motor symptoms such bradykinesia, stiffness and tremors. Inflammation plays a significant role in the development and progression of PD, according to recent research using human samples and animal models. Post-mortem studies on PD brains have revealed elevated amounts of pro-inflammatory cytokines and activated microglia in the afflicted brain areas. Microglia, which are immune cells homing in the brain, are believed to have a significant role in PD inflammation. In reaction to damage or infection, microglia can be activated and release pro-inflammatory cytokines such interleukin-1 beta (IL-1), tumor necrosis factor-alpha (TNFα) and interleukin-6 (IL-6). These cytokines can promote a continuing cycle of damage and inflammation as well as the activation of other immune cells like T cells. Indeed, one study found T cell invasion in the brains of PD patients. Without treating the underlying neurodegeneration, the objectives of current PD treatments are to lessen symptoms and improve quality of life. The preferred method of treating PD is levodopa, a dopamine precursor that can cross the blood-brain barrier and be converted to dopamine in the brain. Unfortunately, chronic intake of levodopa can cause severe motor problems such dyskinesias and wearing off as well as non-motor problems like cognitive decline and psychiatric issues if used long-term. Other drugs used to treat PD include dopamine agonists, catechol-O-methyltransferase (COMT) inhibitors and monoamine oxidase-B (MAO-B) inhibitors. Deep brain stimulation (DBS), a surgical procedure involving the insertion of electrodes to stimulate specific brain regions at determined frequencies, is sometimes used to treat motor complaints. Since all these treatments treat symptoms, there remains a significant unmet need for therapies that can treat or stop the progression of PD. SUMMARY OF THE INVENTION The present inventors have developed a therapeutic approach for PD by leveraging the anti- inflammatory properties of IL-10. In order to treat the inflammatory component of PD, the inventors developed vectors, such as lentiviral vectors, for expressing IL-10 in the brain. In particular, the inventors’ approach harnessed miRNA detargeting methodology to specifically increase IL-10 expression in microglia after intracerebral injection of vectors. Without wishing to be bound by theory, due to the fact that dopaminergic neurons are inherently delicate and sensitive to a variety of genetic and environmental factors, overexpressing a transgene (e.g. IL-10) in these neurons could exacerbate their compromised condition, and the restriction of the expression of the transgene to glial cells is beneficial. The inventors found that the load of overexpressed protein is well tolerated by glial cells, such as microglia, thus minimising possible damage to dopaminergic neurons. The inventors have thoroughly analysed their approach in order to ensure the absence of any negative effects resulting from the expression of the therapeutic gene. This has been achieved using glia as recipient cells for gene delivery. The inventors have been able to avoid potential side effects associated with continuous IL-10 production and achieved a more accurate and controlled therapeutic effect. Negative side effects related to IL-10 continuous release include anaemia as well as permanent immune system suppression which can lead to infections and tumours. To further address this issue and make the expression of IL-10 upregulated only in presence of inflammatory cues, the inventors designed a system to be inducible in response to an increase in the cytokine IFNγ. This approach further reduces the likelihood of negative effects brought on by prolonged exposure to the anti-inflammatory molecule by ensuring that IL-10 is produced in a timely and controlled manner. The inventors’ method provides a new treatment for patients by offering a potent tool to battle the inflammatory processes underlying PD with the capacity to control the time and intensity of IL-10 expression. In particular, the inventors have demonstrated that under their approach, IL-10 may be released from microglia with a sufficient extracellular concentration to achieve a therapeutic impact. The inventors further showed that their approach does not lead to any discernible decline in the number of tyrosine hydroxylase (TH) positive neurons and that no neurotoxic effects on dopaminergic neurons were observed to result from the vector. In one aspect, the invention provides a vector comprising a transgene encoding interleukin 10 (IL-10). The vector preferably targets transgene expression to the central nervous system (CNS), preferably microglia. In one aspect, the invention provides a vector for central nervous system (CNS)-specific expression, wherein the vector comprises a transgene encoding interleukin 10 (IL-10). In some embodiments, the vector is for microglia-specific expression. In one aspect, the invention provides a vector for astrocyte-specific expression, wherein the vector comprises a transgene encoding interleukin 10 (IL-10). The vector may comprise one or more expression control sequence operably linked to the transgene. The one or more expression control sequence may be for astrocyte-specific expression of the transgene. In one aspect, the invention provides a vector for astrocyte-specific expression, wherein the vector comprises a transgene encoding interleukin 10 (IL-10), and wherein the transgene is operably linked to one or more expression control sequence. The vector may comprise one or more expression control sequence operably linked to the transgene. The one or more expression control sequence may be for central nervous system (CNS)-specific (e.g. microglia-specific) expression of the transgene. In one aspect, the invention provides a vector for central nervous system (CNS)-specific expression, wherein the vector comprises a transgene encoding interleukin 10 (IL-10), and wherein the transgene is operably linked to one or more expression control sequence. In one aspect, the invention provides a vector for microglia-specific expression, wherein the vector comprises a transgene encoding interleukin 10 (IL-10), and wherein the transgene is operably linked to one or more expression control sequence. In some embodiments, the one or more expression control sequence comprises one or more miRNA target sequence. In some embodiments, the one or more expression control sequence comprises one or more miRNA target sequence, wherein the one or more miRNA target sequence suppresses expression in cells other than microglia. In some embodiments, the one or more expression control sequence comprises one or more miRNA target sequence, wherein the one or more miRNA target sequence suppresses expression in neurons, oligodendrocytes and / or astrocytes. In some embodiments, the one or more expression control sequence comprises one or more miRNA target sequence, wherein the one or more miRNA target sequence suppresses expression in neurons. In some embodiments, the one or more expression control sequence comprises one or more miRNA target sequence, wherein the one or more miRNA target sequence suppresses expression in oligodendrocytes. In some embodiments, the one or more expression control sequence comprises one or more miRNA target sequence, wherein the one or more miRNA target sequence suppresses expression in astrocytes. In some embodiments, the one or more expression control sequence comprises one or more miRNA target sequence, wherein the one or more miRNA target sequence suppresses expression in neurons, oligodendrocytes and astrocytes. In some embodiments, the one or more expression control sequence comprises at least one miR-124 target sequence, and / or at least one miR-338-3p target sequence, and / or at least one miR-31 target sequence. In some embodiments, the one or more expression control sequence comprises at least one miR-124 target sequence. In some embodiments, the one or more expression control sequence comprises at least one miR-338-3p target sequence. In some embodiments, the one or more expression control sequence comprises at least one miR-31 target sequence. In some embodiments, the one or more expression control sequence comprises at least one miR-124 target sequence, at least one miR-338-3p target sequence and at least one miR-31 target sequence. In some embodiments, the number of copies of each miRNA target sequence is independently selected from the group consisting of: one, two, three and four. In some embodiments, the one or more expression control sequence comprises one miR-124 target sequence. In some embodiments, the one or more expression control sequence comprises two miR-124 target sequences. In some embodiments, the one or more expression control sequence comprises three miR-124 target sequences. In preferred embodiments, the one or more expression control sequence comprises four miR-124 target sequences. In some embodiments, the one or more expression control sequence comprises one miR-31 target sequence. In some embodiments, the one or more expression control sequence comprises two miR-31 target sequences. In some embodiments, the one or more expression control sequence comprises three miR-31 target sequences. In preferred embodiments, the In some embodiments, the one or more expression control sequence comprises one miR-338- 3p target sequence. In some embodiments, the one or more expression control sequence comprises two miR-338-3p target sequences. In some embodiments, the one or more expression control sequence comprises three miR-338-3p target sequences. In preferred embodiments, the one or more expression control sequence comprises four miR-338-3p target sequences. In some embodiments, the one or more expression control sequence comprises four miR-124 target sequences, four miR-338-3p target sequences and four miR-31 target sequences. In some embodiments, the miR-124 target sequence comprises or consists of a nucleotide sequence that has at least 90%, 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO: 1. In some embodiments, the miR-124 target sequence comprises or consists of SEQ ID NO: 1. In some embodiments, the miR-338-3p target sequence comprises or consists of a nucleotide sequence that has at least 90%, 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO: 2. In some embodiments, the miR-338-3p target sequence comprises or consists of SEQ ID NO: 2. In some embodiments, the miR-31 target sequence comprises or consists of a nucleotide sequence that has at least 90%, 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO: 3. In some embodiments, the miR-31 target sequence comprises or consists of SEQ ID NO: 3. In some embodiments, the one or more expression control sequence comprises or consists of a nucleotide sequence that has at least 90%, 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO: 4. In some embodiments, the one or more expression control sequence comprises or consists of SEQ ID NO: 4. In some embodiments, the vector further comprises a promoter operably linked to the transgene. In some embodiments, the promoter is a constitutive promoter or an inducible promoter. In some embodiments, the promoter is a Ef1α promoter or an Mx1 minimal promoter. In some embodiments, the promoter is a Ef1α promoter. In some embodiments, the promoter is an Mx1 minimal promoter. In some embodiments, the promoter comprises or consists of a nucleotide sequence that has at least 70%, 80%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO: 5 or 6. In some embodiments, the promoter comprises or consists of SEQ ID NO: 5 or 6. In some embodiments, the promoter is a GFAP promoter. In some embodiments, the promoter comprises or consists of a nucleotide sequence that has at least 70%, 80%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO: 34. In some embodiments, the promoter comprises or consists of SEQ ID NO: 34. In some embodiments, the vector further comprises one or more gamma activated sequence (GAS) operably linked to the transgene. In some embodiments, the vector further comprises one, two, three or four GASs operably linked to the transgene. In some embodiments, the vector further comprises four GASs operably linked to the transgene. In some embodiments, the GAS comprises or consists of a nucleotide sequence that has at least 90%, 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO: 7. In some embodiments, the GAS comprises or consists of SEQ ID NO: 7. In some embodiments, the one or more expression control sequence comprises at least one miR-124 target sequence and / or at least one miR-338-3p target sequence and / or at least one miR-31 target sequence, and the vector further comprises a promoter and one or more GAS operably linked to the transgene. In some embodiments, the one or more expression control sequence comprises at least one miR-124 target sequence, at least one miR-338-3p target sequence and at least one miR-31 target sequence, and the vector further comprises a promoter and one or more GAS operably linked to the transgene. In some embodiments, the one or more expression control sequence comprises at least one miR-124 target sequence, at least one miR-338-3p target sequence and at least one miR-31 target sequence, and the vector further comprises a promoter and four GASs operably linked to the transgene. In some embodiments, the one or more expression control sequence comprises four miR-124 the vector further comprises a promoter and one or more GAS operably linked to the transgene. In some embodiments, the one or more expression control sequence comprises four miR-124 target sequences, four miR-338-3p target sequences and four miR-31 target sequences, and the vector further comprises a promoter and four GASs operably linked to the transgene. In some embodiments, the IL-10 is human IL-10. In some embodiments, the transgene encoding IL-10 comprises or consists of a nucleotide sequence encoding an amino acid sequence that has at least 70%, 80%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO: 8. In some embodiments, the transgene encoding IL-10 comprises or consists of a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 8. In some embodiments, the transgene encoding IL-10 comprises or consists of a nucleotide sequence that has at least 70%, 80%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO: 9. In some embodiments, the transgene encoding IL-10 comprises or consists of SEQ ID NO: 9. In some embodiments, the vector is a retroviral, lentiviral, AAV or adenoviral vector. In preferred embodiments, the vector is a lentiviral vector. In some embodiments, the vector (e.g. lentiviral vector) comprises or consists of a nucleotide sequence that has at least 70%, 80%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO: 10 or 11. In some embodiments, the vector (e.g. lentiviral vector) comprises or consists of SEQ ID NO: 10 or 11. In some embodiments, the vector is a AAV vector. In some embodiments, the vector (e.g. AAV vector) comprises or consists of a nucleotide sequence that has at least 70%, 80%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO: 35. In some embodiments, the vector (e.g. AAV vector) comprises or consists of SEQ ID NO: 35. In some embodiments, the vector is in the form of a viral vector particle. In some embodiments, the viral vector particle is a VSV-g pseudotyped viral vector particle. In some embodiments, the vector is replication-incompetent. In some embodiments, the vector is an AAV vector particle, wherein the AAV vector particle comprises a capsid selected from the group consisting of an AAV9; AAV9 PHP.B; AAV9 PHP.eB; and AAVrh10 capsid. In some embodiments, the vector is an AAV vector particle for astrocyte-specific expression. The AAV vector particle may, for example, be of a serotype for astrocyte-specific expression. In some embodiments, the AAV vector particle displays tropism for astrocytes. In some embodiments, the AAV vector particle comprises a capsid selected from the group consisting of AAV1, AAV2, AAV1 / 2 and PHP.eB. In one aspect, the invention provides a cell comprising the vector of the invention. In one aspect, the invention provides a pharmaceutical composition comprising the vector or cell of the invention and a pharmaceutically-acceptable carrier, diluent or excipient. In one aspect, the invention provides the vector, cell or pharmaceutical composition of the invention for use in therapy. In one aspect, the invention provides use of the vector, cell or pharmaceutical composition of the invention for the manufacture of a medicament. In one aspect, the invention provides a method of treatment comprising administering the vector, cell or pharmaceutical composition of the invention to a subject in need thereof. The vector, cell or pharmaceutical composition may, for example, be used in treating or preventing a neurodegenerative disease. The vector, cell or pharmaceutical composition may, for example, be used in treating or preventing Parkinson’s disease. The vector, cell or pharmaceutical composition may, for example, be used in treating or preventing Alzheimer’s disease, frontotemporal dementia, Pick disease, Multiple systemic atrophy (MSA) or multiple sclerosis. In one aspect, the invention provides the vector, cell or pharmaceutical composition of the invention for use in treating or preventing Parkinson’s disease. In one aspect, the invention provides use of the vector, cell or pharmaceutical composition of the invention for the manufacture of a medicament for treating or preventing Parkinson’s In one aspect, the invention provides a method of treating or preventing Parkinson’s disease comprising administering the vector, cell or pharmaceutical composition of the invention to a subject in need thereof. In some embodiments, the vector, cell or pharmaceutical composition is administered to a subject systemically or locally. In some embodiments, the vector, cell or pharmaceutical composition is administered to a subject intracranially or intraparenchymally. In some embodiments, the vector, cell or pharmaceutical composition is administered to a subject intracerebrally. In some embodiments, the vector, cell or pharmaceutical composition is used in combination with another treatment for Parkinson’s disease, for example administration of levodopa, administration of a dopamine agonist, administration of a catechol-O-methyltransferase (COMT) inhibitor, administration of a monoamine oxidase-B (MAO-B) inhibitor, and / or deep brain stimulation (DBS). In some embodiments, the vector, cell or pharmaceutical composition is used in combination with dopamine replacement therapy (DRT). DESCRIPTION OF THE DRAWINGS FIGURE 1 (A) Representation of the IL-10 construct for the specific expression in microglia. (B) Level of GFP transcripts in microglia primary culture infected with LV-miRTag-GFP and measured with RT-PCR. (C) SNpc infected tissue with LV-miRTag-GFP and stained for the measurement of GFP colocalization with astrocytes (GFAP), microglia (IBA1), neurons (NeuN) and oligodendrocytes (Olig2). The degree of colocalization indicates the selective expression of GFP in microglia. (D) Level of the expressed IL-10 in the nigral tissue lysate and released extracellularly (E) measured by ELISA. ***p<0.001. FIGURE 2 Immunohistochemical analysis of the total number of the dopaminergic neurons stained with TH and counted with unbiased stereology. ***p<0.001. FIGURE 3 (A) Schematic of a platform using four copies of GAS before a Mx1 minimum promoter (B) Immunofluorescence images demonstrating enhanced GFP expression in microglia primary cultures infected with LV-4GAS-mMX1-GFP in response to IFN gamma treatment. (C) RT- PCR quantification of IL-10 transcription in microglia primary cultures infected with LV-4GAS- mMX1-IL10 and expressed as fold change vs IFN gamma untreated cells. FIGURE 4 (A-C) Examination of microglial activation and phagocytic function in the SNpc carried out by immunodecoration for CD68, IBA1 and a marker for αSYN aggregates pS129αSYN. The quantification of CD68 particles within individual cells was performed in terms of the number per unit area (B) and their average size (C). The magnified inset in (A) highlights the co- localization of αSYN aggregates with CD68-positive particles. (D, E) Expression of human αSYN and presence of αSYN aggregates within the nigral tissue in the different conditions, quantified as the percentage of the stained area. (F-H) Quantification of αSYN aggregates as the percentage of pS129αSYN stained area in proteinase K-treated nigral slices. All data are presented as the mean ± s.e.m. and were subjected to analysis using one-way ANOVA followed by Tukey’s multiple comparisons test. *p<0.05; ***p<0.001; ****p<0.0001; ns, not significant. Scale bars: (A, D) 50 µm, (A, inset) 25 µm; (F) 300 µm. FIGURE 5 (A, C) In vitro phagocytosis assay using primary microglia infected with LV:Nluc, LV:µgIL10, LV:SNCA and LV:SNCA / µgIL10 and seeded with fluorescent αSYN pre-formed fibrils (Fluor488-PFFs). Phagocytosis is measured by the area occupied by Fluor488-PFFs signal within microglia (IBA1). (B, D, E) In vitro phagocytosis assay employing primary microglia infected with LV:Nluc, LV:µgIL10, LV:SNCA and LV:SNCA / µgIL10 and seeded with pHrodo- labelled synaptosomes. The quantification is carried out by measuring the intensity (E) and the number of pHrodo+particles (D). All data are presented as the mean ± s.e.m. and were subjected to analysis using one-way ANOVA followed by Tukey’s multiple comparisons test. *p<0.05; ***p<0.001; ****p<0.0001; ns, not significant. Scale bar 50 µm. DETAILED DESCRIPTION OF THE INVENTION The terms “comprising”, “comprises” and “comprised of” as used herein are synonymous with “including” or “includes”; or “containing” or “contains”, and are inclusive or open-ended and do not exclude additional, non-recited members, elements or steps. The terms “comprising”, “comprises” and “comprised of” also include the term “consisting of”. In one aspect, the invention provides a vector for central nervous system (CNS)-specific expression, wherein the vector comprises a transgene encoding interleukin 10 (IL-10). The “central nervous system” as used herein means the nervous system consisting of the brain and spinal cord. The “peripheral nervous system” as used herein means the components of the nervous system outside of the central nervous system. The peripheral nervous system consists of the nerves and ganglia outside of the brain and spinal cord. The term “blood brain barrier” (BBB) as used herein means the highly selective semi- permeable membrane barrier which separates the circulating blood from the brain and extracellular fluid in the central nervous system. It is formed by the selectivity of tight junctions between endothelial cells. The blood-brain barrier occurs along all capillaries of the brain and consists of tight junctions. As used herein “brain endothelial cells”, “brain endothelium” or “brain microvascular endothelial cells” may refer to the cerebral endothelial cells that present the interface between the blood and the central nervous system, i.e. blood-brain barrier endothelial cells. Suitably the brain endothelial cells may form the blood-brain barrier. Microglia In some embodiments, the vector is for microglia-specific expression. Microglia are a type of glial cell located in the central nervous system, and account for about 10-15% of cells in the brain. Microglia are the resident macrophage cells that act as the main form of immune defence in the central nervous system. Macrophages are innate immune cells that clear tissue from pathogens or other biological material. In adult mammals, macrophages are found in all tissues where they display great anatomical and functional diversity. In tissues, they are organized in defined patterns with each cell occupying its own territory. Microglia contribute to brain maintenance, for example by scavenging for plaques, damaged or unnecessary neurons and synapses, and infectious agents. The skilled person is readily able to identify cells such as macrophages and microglia, for example using markers that may be expressed on a cell surface. For example, ionized calcium-binding adaptor molecule 1 (Iba1) is a microglial and macrophage-specific calcium- binding protein involved with membrane ruffling and phagocytosis in activated microglia, which may be used in identification. CD11b and CD45 markers may be used to distinguish microglia from macrophages. Resting microglia are CD11bhiCD45low, whereas macrophages are CD11bhiCD45hi. Specific-expression The vector may be a central nervous system (CNS)-specific expression vector, preferably a microglia-specific expression vector. The terms “CNS-specific expression” and “microglia- specific expression”, as used herein, may refer to the preferential or predominant expression of a transgene in the CNS or microglia, respectively, as compared to other cells (e.g. blood, lung and bone marrow cells). In some embodiments, at least 50% of transgene expression occurs in the microglia. In some embodiments, at least 60%, 70%, 80%, 90% or 95% of transgene expression occurs in the microglia. In some embodiments, the transgene is substantially exclusively expressed in the microglia. For example: (i) expression of the transgene in microglia transduced by the vector may be greater than expression of the transgene in other cells transduced by the vector; (ii) the transgene may be substantially not expressed in cells other than the microglia, when transduced by the vector; (iii) the transgene may be substantially not expressed in neurons, oligodendrocytes and / or astrocytes, when transduced by the vector; (iv) expression of the transgene in microglia may be at least five times greater than expression in neurons, oligodendrocytes and / or astrocytes, when transduced by the vector; and / or (v) the transgene may be substantially not expressed in neurons, oligodendrocytes and / or astrocytes when transduced by the vector. Expression of the transgene may be determined by any suitable method known to the skilled person, for example any of the methods as disclosed herein. Suitably, expression of the transgene in microglia transduced by the vector may be greater than expression of the transgene in other cells transduced by the vector. For example, expression of the transgene in microglia transduced by the vector may be at least 5 times, at least 10 times, at least 20 times, at least 50 times, or at least 100 times greater than in other cells transduced by the vector. Suitably, the transgene is substantially not expressed in cells other than the microglia, when transduced by the vector. For example, the percentage of the cells other than the microglia which express the transgene may be 15% or less, 10% or less, 5% or less, 2% or less, 1% or less, or 0%. For example, expression of the transgene in cells other than the microglia may be undetectable. Suitably, the transgene is substantially not expressed in neurons, oligodendrocytes and / or astrocytes, when transduced by the vector. For example, the percentage of neurons, oligodendrocytes and / or astrocytes which express the transgene may be 15% or less, 10% or less, 5% or less, 2% or less, 1% or less, or 0%. For example, expression of the transgene in neurons, oligodendrocytes and / or astrocytes may be undetectable. Suitably, the transgene is substantially only expressed in microglia. The percentage of the cells types other than microglia which express the transgene may, for example, be 15% or less, 10% or less, 5% or less, 2% or less, 1% or less, or 0%. For example, expression of the transgene in cell types other than microglia may be undetectable. Suitably, expression of the transgene in microglia may be at least five times greater than expression in neurons, oligodendrocytes and / or astrocytes, when transduced by the vector. For example, expression of the transgene in microglia may be at least ten times greater, at least twenty times greater, or at least fifty times greater than expression in neurons, oligodendrocytes and / or astrocytes. Suitably, the transgene may be substantially not expressed in neurons, oligodendrocytes and / or astrocytes when transduced by the vector. For example, the percentage of neurons, oligodendrocytes and / or astrocytes which express the transgene may be 5% or less, 2% or less, 1% or less, or 0%. For example, expression of the transgene in neurons, oligodendrocytes and / or astrocytes may be undetectable. EXPRESSION CONTROL SEQUENCES The vector of the invention may comprise one or more expression control sequence. Suitably, the transgene is operably linked to one or more expression control sequence. As used herein an “expression control sequence” is a nucleotide sequence that controls expression of a transgene, e.g. to facilitate and / or increase expression in some cell types d / d i i th ll t The expression control sequence and the transgene may be in any suitable arrangement in the vector, for example providing that the expression control sequence is operably linked to the transgene. The term “operably linked”, as used herein, means that the parts (e.g. transgene and one or more expression control sequence) are linked together in a manner which enables both to carry out their function substantially unhindered. The expression control sequence may be a central nervous system (CNS)-specific expression control sequence, particularly a microglia-specific expression control sequence (e.g. such that the vector specifically expresses a transgene in the CNS, particularly microglia). Expression control sequences include promoters, enhancers, and 5’ and 3’ untranslated regions (e.g. miRNA target sequences). The one or more expression control sequence may comprise one or more miRNA target sequence. In some embodiments, the one or more expression control sequence comprises a promoter and one or more miRNA target sequence. In some embodiments, the one or more expression control sequence comprises a promoter, one or more gamma activated sequence (GAS) and one or more miRNA target sequence. The vector may, for example, comprise from 5’ to 3’: a promoter; the transgene; and one or more miRNA target sequence. The vector may, for example, comprise from 5’ to 3’: one or more GAS; a promoter; the transgene; and one or more miRNA target sequence. MicroRNA target sequences In some embodiments, the vector comprises one or more miRNA target sequence. Suitably, the transgene encoding IL-10 is operably linked to the one or more miRNA target sequence. MicroRNA (miRNA) genes are scattered across all human chromosomes, except for the Y chromosome. They can be either located in non-coding regions of the genome or within introns of protein-coding genes. Around 50% of miRNAs appear in clusters which are transcribed as polycistronic primary transcripts. Similar to protein-coding genes, miRNAs are usually transcribed from polymerase-II promoters, generating a so-called primary miRNA transcript (pri-miRNA). This pri-miRNA is then processed through a series of endonucleolytic cleavage steps, performed by two enzymes belonging to the RNAse Type III family, Drosha and Dicer. From the pri-miRNA, a stem loop of about 60 nucleotides in length, called miRNA precursor (pre-miRNA), is excised by a specific nuclear complex, composed of Drosha and DiGeorge syndrome critical region gene (DGCR8), which crops both strands near the base of the primary actively transported from the nucleus to the cytoplasm by RAN-GTP and Exportin. Then, Dicer performs a double strand cut at the end of the stem loop not defined by the Drosha cut, generating a 19-24 bp duplex, which is composed of the mature miRNA and the opposite strand of the duplex, called miRNA*. In agreement with the thermodynamic asymmetry rule, only one strand of the duplex is selectively loaded into the RNA-induced silencing complex (RISC), and accumulates as the mature microRNA. This strand is usually the one whose 5’ end is less tightly paired to its complement, as was demonstrated by single-nucleotide mismatches introduced into the 5’ end of each strand of siRNA duplexes. However, there are some miRNAs that support accumulation of both duplex strands to similar extent. MicroRNAs trigger RNAi, very much like small interfering RNAs (siRNA) which are extensively used for experimental gene knockdown. The main difference between miRNA and siRNA is their biogenesis. Once loaded into RISC, the guide strand of the small RNA molecule interacts with mRNA target sequences preferentially found in the 3' untranslated region (3'UTR) of protein-coding genes. It has been shown that nucleotides 2-8 counted from the 5' end of the miRNA, the so-called seed sequence, are essential for triggering RNAi. If the whole guide strand sequence is perfectly complementary to the mRNA target, as is usually the case for siRNAs and plant miRNAs, the mRNA is endonucleolytically cleaved by involvement of the Argonaute (Ago) protein, also called “slicer” of the small RNA duplex into the RNA-induced silencing complex (RISC). DGRC (DiGeorge syndrome critical region gene 8) and TRBP (TAR (HIV) RNA binding protein 2) are double-stranded RNA-binding proteins that facilitate mature miRNA biogenesis by Drosha and Dicer RNase III enzymes, respectively. The guide strand of the miRNA duplex gets incorporated into the effector complex RISC, which recognises specific targets through imperfect base-pairing and induces post-transcriptional gene silencing. Several mechanisms have been proposed for this mode of regulation: miRNAs can induce the repression of translation initiation, mark target mRNAs for degradation by deadenylation, or sequester targets into the cytoplasmic P-body. On the other hand, if only the seed is perfectly complementary to the target mRNA but the remaining bases show incomplete pairing, RNAi acts through multiple mechanisms leading to translational repression. Eukaryotic mRNA degradation mainly occurs through the shortening of the polyA tail at the 3’ end of the mRNA, and de-capping at the 5’ end, followed by 5’-3’ exonuclease digestion and accumulation of the miRNA in discrete cytoplasmic areas, the so called P-bodies, enriched in components of the mRNA decay pathway. Expression of the nucleic acid sequence encoding the transgene may be regulated by one or more endogenous miRNA using one or more corresponding miRNA target sequence. Using transgene expression in that cell by binding to its corresponding miRNA target sequence positioned in the polynucleotide or vector. The target sequence may be fully or partially complementary to the miRNA. The term “fully complementary”, as used herein, may mean that the target sequence has a nucleic acid sequence which is 100% complementary to the sequence of the miRNA which recognises it. The term “partially complementary”, as used herein, may mean that the target sequence is only in part complementary to the sequence of the miRNA which recognises it, whereby the partially complementary sequence is still recognised by the miRNA. In other words, a partially complementary target sequence in the context of the present invention is effective in recognising the corresponding miRNA and effecting prevention or reduction of transgene expression in cells expressing that miRNA. Suitably, a partially complementary miRNA target sequence may be fully complementary to the miRNA seed sequence. In one aspect, the invention provides a vector comprising a transgene encoding interleukin 10 (IL-10) and at least one miR-124 target sequence. In one aspect, the invention provides a vector comprising a transgene encoding interleukin 10 (IL-10) and at least one miR-31 target sequence. In one aspect, the invention provides a vector comprising a transgene encoding interleukin 10 (IL-10) and at least one miR-338-3p target sequence. In one aspect, the invention provides a vector comprising a transgene encoding interleukin 10 (IL-10) and at least one miR-124 target sequence and at least one miR-31 target sequence. In one aspect, the invention provides a vector comprising a transgene encoding interleukin 10 (IL-10) and at least one miR-124 target sequence and at least one miR-338-3p target sequence. In one aspect, the invention provides a vector comprising a transgene encoding interleukin 10 (IL-10) and at least one miR-124 target sequence, at least one miR-31 target sequence and at least one miR-338-3p target sequence. Including more than one copy of a miRNA target sequence may increase the effectiveness of the system. Also, different miRNA target sequences can be included. For example, the protein- coding sequence may be operably linked to more than one miRNA target sequence, which may or may not be different. The miRNA target sequences may be in tandem, but other arrangements are envisaged. The polynucleotide may, for example, comprise 1, 2, 3, 4, 5, 6, 7 or 8 copies of the same or different miRNA target sequences. Copies of miRNA target sequences may be separated by a spacer sequence. The spacer sequence may comprise, for example, at least one, at least two, at least three, at least four or at least five nucleotide bases. In some embodiments, the number of copies of each of the miRNA target sequences is independently selected from the group consisting of: one, two, three, and four. In some embodiments, the vector comprises one miR-124 target sequence. In some embodiments, the vector comprises two miR-124 target sequences. In some embodiments, the vector comprises three miR-124 target sequences. In preferred embodiments, the vector comprises four miR-124 target sequences. In some embodiments, the vector comprises one miR-31 target sequence. In some embodiments, the vector comprises two miR-31 target sequences. In some embodiments, the vector comprises three miR-31 target sequences. In preferred embodiments, the vector comprises four miR-31 target sequences. In some embodiments, the vector comprises one miR-338-3p target sequence. In some embodiments, the vector comprises two miR-338-3p target sequences. In some embodiments, the vector comprises three miR-338-3p target sequences. In preferred embodiments, the vector comprises four miR-338-3p target sequences. In preferred embodiments, the vector comprises four miR-124 target sequences, four miR-31 target sequences and four miR-338-3p target sequences. An exemplary miR-124 target sequence is: TATTGCCTTATTTC (SEQ ID NO: 1) In some embodiments, the miR-124 target sequence comprises or consists of a nucleotide sequence that has at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 1. In some embodiments, the miR-124 target sequence comprises or consists of a nucleotide sequence that has at least 90% sequence identity to SEQ ID NO: 1. In some embodiments, the miR-124 target sequence comprises or consists of the nucleotide sequence of SEQ ID NO: 1. An exemplary miR-338-3p target sequence is: CAACAAAATCACTGATGCTGGA (SEQ ID NO: 2) In some embodiments, the miR-338-3p target sequence comprises or consists of a nucleotide sequence that has at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 2. In some embodiments, the miR-338-3p target sequence comprises or consists of a nucleotide sequence that has at least 90% sequence identity to SEQ ID NO: 2. In some embodiments, the miR-338-3p target sequence comprises or consists of the nucleotide sequence of SEQ ID NO: 2. An exemplary miR-31 target sequence is: CAGCTATGCCAGCATCTTGCC (SEQ ID NO: 3) In some embodiments, the miR-31 target sequence comprises or consists of a nucleotide sequence that has at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 3. In some embodiments, the miR-31 target sequence comprises or consists of a nucleotide sequence that has at least 90% sequence identity to SEQ ID NO: 3. In some embodiments, the miR-31 target sequence comprises or consists of the nucleotide sequence of SEQ ID NO: 3. In some embodiments, the miRNA target sequences or clusters of copies of the miRNA target sequences are, from 5’ to 3’, arranged in the order: miR-124 target sequence(s), miR-338-3p target sequence(s) and miR-31 target sequence(s). The target sequences, or clusters comprising one or more copy thereof, may be, for example, arranged from 5’ to 3’ such that they form groups according to their target specificity, for example, in some embodiments the vector comprises 5’ – [miR-124 target sequence]4– [miR-338-3p target sequence]4– [miR-31 target sequence]4– 3’. In some embodiments, the miRNA target sequences or clusters of copies of sequences are, from 5’ to 3’, arranged in the order: miR-124, miR-31 and miR-338-3p. In some embodiments, the miRNA target sequences or clusters of copies of sequences are, from 5’ to 3’, arranged in the order: miR-338-3p, miR-124 and miR-31. In some embodiments, the miRNA target sequences or clusters of copies of sequences are, In some embodiments, the miRNA target sequences or clusters of copies of sequences are, from 5’ to 3’, arranged in the order: miR-31, miR-124 and miR-338-3p. In some embodiments, the miRNA target sequences or clusters of copies of sequences are, from 5’ to 3’, arranged in the order: miR-31, miR-338-3p and miR-124. An exemplary triple miRNA target sequence combination is: TATTGCCTTATTTCCGATTATTGCCTTATTTCGCATTATTGCCTTATTTCTCACTATTGCCTTATTTC CGATCCCGGGGTTTAAACCGATCAACAAAATCACTGATGCTGGACGATCAACAAAATCACTGATGCTG GACGATCAACAAAATCACTGATGCTGGATCACCAACAAAATCACTGATGCTGGACGATGTTTAAACCC TGCAGGCGATCAGCTATGCCAGCATCTTGCCCGATCAGCTATGCCAGCATCTTGCCCGATCAGCTATG CCAGCATCTTGCCTCACCAGCTATGCCAGCATCTTGCC (SEQ ID NO: 4) miR-124 target sequence: Double underline miR-338-3p target sequence: Dashed underline miR-31 target sequence: Dotted underline In some embodiments, the vector comprises a nucleotide sequence that has at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 4. In some embodiments, the polynucleotide comprises a nucleotide sequence that has at least 90% sequence identity to SEQ ID NO: 4. In some embodiments, the polynucleotide comprises the nucleotide sequence of SEQ ID NO: 4. In some embodiments, the one or more miRNA target sequence suppresses transgene expression in neurons. In some embodiments, the one or more miRNA target sequence suppresses transgene expression in astrocytes. In some embodiments, the one or more miRNA target sequence suppresses transgene expression in oligodendrocytes. The term “suppress expression” as used herein may refer to a reduction of expression in the relevant cell type(s) of a transgene to which the one or more miRNA target sequence is operably linked as compared to transgene expression in the absence of the one or more miRNA target sequence, but under otherwise substantially identical conditions. In some transgene expression is suppressed by at least 60%, 70%, 80%, 90% or 95%. In some embodiments, transgene expression is undetectable. In some embodiments, transgene expression is substantially prevented. Both the individual target sequences and the clusters of sequences may be contiguous with one another, separated by spacer sequences, or any combination thereof. In some embodiments, the miRNA target sequences are separated by spacer sequences. As used herein, a “spacer” may be a sequence (e.g. a nucleotide or amino acid sequence) that may be used to separate other sequence elements within a larger polymer. Individual miRNA target sequences or groups of miRNA target sequences may be separated by one or more spacer sequence. In some embodiments, the miRNA target sequences are separated by one or more spacer sequence. The spacer sequence may comprise, for example, at least one, at least two, at least three, at least four, at least five, at least ten, at least twenty, or at least thirty nucleotide bases. Promoter In some embodiments, the vector further comprises a promoter operably linked to the transgene. In some embodiments, the promoter is a constitutive promoter or an inducible promoter. As used herein, an “inducible promoter” is a promoter which is only active under specific conditions. For example, expression of the transgene may be induced by a small molecule or drug (e.g. which binds to a promoter, regulatory sequence or to a transcriptional repressor or activator molecule) or by using an environmental trigger. Types of inducible promoter include chemically-inducible promoters (e.g. a Tet-on system); temperature-inducible promoters (e.g. Hsp70 or Hsp90-derived promoters); and light-inducible promoters. Suitably, the promoter is chemically-inducible. As used herein, a “constitutive promoter” is a promoter which is always active. In some embodiments, the promoter is a Ef1α promoter. An exemplary Ef1α promoter sequence is: CGATAAGCTTTGCAAAGATGGATAAAGTTTTAAACAGAGAGGAATCTTTGCAGCTAATGGACCTTCTA GGTCTTGAAAGGAGTGGGAATTGGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCC GAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGT AGTCGCCGTGAACGTTCTTTTTCGCAACGGGTTTGCCGCCAGAACACAGGTAAGTGCCGTGTGTGGTT CCCGCGGGCCTGGCCTCTTTACGGGTTATGGCCCTTGCGTGCCTTGAATTACTTCCACTGGCTGCAGT ACGTGATTCTTGATCCCGAGCTTCGGGTTGGAAGTGGGTGGGAGAGTTCGAGGCCTTGCGCTTAAGGA GCCCCTTCGCCTCGTGCTTGAGTTGAGGCCTGGCCTGGGCGCTGGGGCCGCCGCGTGCGAATCTGGTG GCACCTTCGCGCCTGTCTCGCTGCTTTCGATAAGTCTCTAGCCATTTAAAATTTTTGATGACCTGCTG CGACGCTTTTTTTCTGGCAAGATAGTCTTGTAAATGCGGGCCAAGATCTGCACACTGGTATTTCGGTT TTTGGGGCCGCGGGCGGCGACGGGGCCCGTGCGTCCCAGCGCACATGTTCGGCGAGGCGGGGCCTGCG AGCGCGGCCACCGAGAATCGGACGGGGGTAGTCTCAAGCTGGCCGGCCTGCTCTGGTGCCTGGCCTCG CGCCGCCGTGTATCGCCCCGCCCTGGGCGGCAAGGCTGGCCCGGTCGGCACCAGTTGCGTGAGCGGAA AGATGGCCGCTTCCCGGCCCTGCTGCAGGGAGCTCAAAATGGAGGACGCGGCGCTCGGGAGAGCGGGC GGGTGAGTCACCCACACAAAGGAAAAGGGCCTTTCCGTCCTCAGCCGTCGCTTCATGTGACTCCACGG AGTACCGGGCGCCGTCCAGGCACCTCGATTAGTTCTCGAGCTTTTGGAGTACGTCGTCTTTAGGTTGG GGGGAGGGGTTTTATGCGATGGAGTTTCCCCACACTGAGTGGGTGGAGACTGAAGTTAGGCCAGCTTG GCACTTGATGTAATTCTCCTTGGAATTTGCCCTTTTTGAGTTTGGATCTTGGTTCATTCTCAAGCCTC AGACAGTGGTTCAAAGTTTTTTTCTTCCATTTCAGGTGTCGTGAGGAATTCTGCAGTCGATCGACGGT ACCGCGGGCCCG (SEQ ID NO: 5) In some embodiments, the promoter comprises or consists of a nucleotide sequence that has at least 70%, 80%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO: 5. In some embodiments, the promoter comprises or consists of SEQ ID NO: 5. In some embodiments, the promoter is an Mx1 minimal promoter. An exemplary Mx1 minimal promoter sequence is: GAGCTGGGGGATGTTCTCTGCAGAGCAGGGCTCTCCTCTGGAGAGAAGGGCAAGGTGCAGCAGGCCCC AGAAGGCCAGCACTTCTCACCCCCACCAGCCCTGCAGTAGCAGTGTGCTCAGACCTCTAAACCTGTAG TCACAAGGGACCCAGAAGGGCTGGCAGGGCTCCTCAGTGATTCTGGTATGGTTTGTCTCTGACCCTTC CTAGTGTAGCTGGAAGAATCCAGTGAAAAGAGAAAGTTAGTCTAGGTTGTGTTCAACTGAGAGGAGGT CAGGCTGAAGGCTCAGCACAGAGCTGGAAGGGTCCTGGGAAAGCAGGCAGCCATCTGAACTGGTGTCC ATACTGCATGTGTCTTGGTGGGCTGAGCCTACAATATCGATTTCCCAACCTCAGTACCAAGCCAAGGC CCCTCAGGGTGAGTTTCGTTTCTGAGCTCCTTTCATATGTGGTGGGGGTGTGGGCACAGCAAGCTCAG GCTTTTTCACGGTTTCAATTCTCCTCTGGAAGGGGTGGAGCCAGCACTATTTAAAGAGGTCTGAGCCC TGGCAGCTGCACACTCTCT In some embodiments, the promoter comprises or consists of a nucleotide sequence that has at least 70%, 80%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO: 6. In some embodiments, the promoter comprises or consists of SEQ ID NO: 6. In some embodiments, the promoter is a GFAP promoter. A GFAP promoter may target expression to astrocytes. An exemplary GFAP promoter sequence is: AACATATCCTGGTGTGGAGTAGGGGACGCTGCTCTGACAGAGGCTCGGGGGCCTGAGCTGGCTCTGTG AGCTGGGGAGGAGGCAGACAGCCAGGCCTTGTCTGCAAGCAGACCTGGCAGCATTGGGCTGGCCGCCC CCCAGGGCCTCCTCTTCATGCCCAGTGAATGACTCACCTTGGCACAGACACAATGTTCGGGGTGGGCA CAGTGCCTGCTTCCCGCCGCACCCCAGCCCCCCTCAAATGCCTTCCGAGAAGCCCATTGAGCAGGGGG CTTGCATTGCACCCCAGCCTGACAGCCTGGCATCTTGGGATAAAAGCAGCACAGCCCCCTAGGGGCTG CCCTTGCTGTGTGGCGCCACCGGCGGTGGAGAACAAGGCTCTATTCAGCCTGTGCCCAGGAAAGGGGA TCAGGGGATGCCCAGGCATGGACAGTGGGTGGCAGGGGGGGAGAGGAGGGCTGTCTGCTTCCCAGAAG TCCAAGGACACAAATGGGTGAGGGGAGAGCTCTCCCCATAGCTGGGCTGCGGCCCAACCCCACCCCCT CAGGCTATGCCAGGGGGTGTTGCCAGGGGCA (SEQ ID NO: 34) In some embodiments, the promoter comprises or consists of a nucleotide sequence that has at least 70%, 80%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO: 34. In some embodiments, the promoter comprises or consists of SEQ ID NO: 34. Gamma activated sequence (GAS) In some embodiments, the vector further comprises one or more gamma activated sequence (GAS) operably linked to the transgene. GAS may be triggered by interferon gamma signalling and may be harnessed to render transgene expression inducible, for example by interferon gamma. An exemplary GAS is: TTCCCGGAA (SEQ ID NO: 7) In some embodiments, the GAS comprises or consists of a nucleotide sequence that has at In some embodiments, the GAS comprises or consists of SEQ ID NO: 7. In some embodiments, the vector further comprises one, two, three or four GASs operably linked to the transgene. In some embodiments, the vector further comprises four GASs operably linked to the transgene. TTCCCGGAATTCCCGGAATTCCCGGAATTCCCGGAA (SEQ ID NO: 12) In some embodiments, the vector further comprises a nucleotide sequence that has at least 90%, 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO: 12. In some embodiments, the vector further comprises SEQ ID NO: 12. Other expression control sequences The vector of the present invention may further comprise one or more regulatory elements which may act pre- or post-transcriptionally. Suitably, the transgene is operably linked to one or more regulatory elements which may act pre- or post-transcriptionally. The one or more regulatory elements may facilitate expression of the transgene in microglia. A “regulatory element” is any nucleotide sequence which facilitates expression of a polypeptide, e.g. acts to increase expression of a transcript or to enhance mRNA stability. Suitable regulatory elements include for example promoters, enhancer elements, post- transcriptional regulatory elements and polyadenylation sites. Post-transcriptional regulatory elements The vector of the invention may comprise one or more post-transcriptional regulatory element. Suitably, the transgene is operably linked to one or more post-transcriptional regulatory element. The post-transcriptional regulatory element may improve gene expression. The vector of the invention may comprise a Woodchuck Hepatitis Virus Post-transcriptional Regulatory Element (WPRE). Suitably, the transgene is operably linked to a WPRE. Suitable WPRE sequences will be well known to those of skill in the art (see, for example, Zufferey et al. (1999) Journal of Virology 73: 2886-2892; Zanta-Boussif et al. (2009) Gene Therapy 16: 605-619). Suitably, the WPRE is a wild-type WPRE or is a mutant WPRE. For example, the WPRE may be mutated to abrogate translation of the woodchuck hepatitis virus X protein (WHX), for example by mutating the WHX ORF translation start codon. In some embodiments, the WPRE comprises or consists of a nucleotide sequence that has at least 70% sequence identity to SEQ ID NO: 13 or a fragment thereof. Suitably, the WPRE comprises or consists of a nucleotide sequence that has at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 13 or a fragment thereof. In some embodiments, the WPRE comprises or consists of the nucleotide sequence SEQ ID NO: 13 or a fragment thereof. AATCAACCTCTGGATTACAAAATTTGTGAAAGATTGACTGGTATTCTTAACTATGTTGCTCCTTTTAC GCTATGTGGATACGCTGCTTTAATGCCTTTGTATCATGCTATTGCTTCCCGTATGGCTTTCATTTTCT CCTCCTTGTATAAATCCTGGTTGCTGTCTCTTTATGAGGAGTTGTGGCCCGTTGTCAGGCAACGTGGC GTGGTGTGCACTGTGTTTGCTGACGCAACCCCCACTGGTTGGGGCATTGCCACCACCTGTCAGCTCCT TTCCGGGACTTTCGCTTTCCCCCTCCCTATTGCCACGGCGGAACTCATCGCCGCCTGCCTTGCCCGCT GCTGGACAGGGGCTCGGCTGTTGGGCACTGACAATTCCGTGGTGTTGTCGGGGAAATCATCGTCCTTT CCTTGGCTGCTCGCCTGTGTTGCCACCTGGATTCTGCGCGGGACGTCCTTCTGCTACGTCCCTTCGGC CCTCAATCCAGCGGACCTTCCTTCCCGC (SEQ ID NO: 13) Polyadenylation sequence The vector of the invention may comprise a polyadenylation sequence. Suitably, the transgene is operably linked to a polyadenylation sequence. A polyadenylation sequence may be inserted after the transgene to improve transgene expression. A polyadenylation sequence typically comprises a polyadenylation signal, a polyadenylation site and a downstream element: the polyadenylation signal comprises the sequence motif recognised by the RNA cleavage complex; the polyadenylation site is the site of cleavage at which a poly-A tail is added to the mRNA; the downstream element is a GT-rich region which usually lies just downstream of the polyadenylation site, which is important for efficient processing. Suitable polyadenylation sequences will be well known to those of skill in the art (see, for example, Schambach et al. (2007) Molecular Therapy 15: 1167-1173; Choi et al. (2014) Molecular Brain 7: 1-10). Exemplary polyadenylation sequences include the bGH poly(A) signal sequence and SV40pA signal sequence. Kozak sequence The vector of the invention may comprise a Kozak sequence. Suitably, the transgene is operably linked to a Kozak sequence. A Kozak sequence may be inserted before the start codon to improve the initiation of translation. Suitable Kozak sequences will be well known to the skilled person (see, for example, Kozak (1987) Nucleic Acids Research 15: 8125-8148). In some embodiments, the Kozak sequence comprises or consists of a nucleotide sequence that has at least 80% sequence identity to SEQ ID NO: 14 or a fragment thereof. In some embodiments, the Kozak sequence comprises or consists of the nucleotide sequence SEQ ID NO: 14 or a fragment thereof. GCCACC (SEQ ID NO: 14) Other cis-acting elements The vector (e.g. lentiviral vector) of the invention may comprise any other suitable cis-acting elements, such as one or more of a rev response element (RRE); a retroviral psi packaging element; a primer binding site (PBS); a TAT activation region (TAR); splice donor and acceptor sites; and central and terminal polypurine tracts. Long terminal repeats (LTRs) The vector (e.g. lentiviral vector) of the invention may comprise one or more long terminal repeat (LTR). LTRs are responsible for proviral integration and transcription. Typically, a naturally occurring LTR comprises U3, R, and U5 regions. The vector (e.g. lentiviral vector) may comprise a 5’ LTR and / or a 3’ LTR. The vector (e.g. lentiviral vector) may comprise a 5’ LTR and a 3’ LTR. Suitably, a 5’ LTR comprises R and U5 regions, and optionally comprises a U3 region. Suitably, a 3’ LTR comprises U3, R and U5 regions. Suitable LTR sequences will be well known to the skilled person (see, for example, Frech et al. (1996) Virology 224: 256-267). In some embodiments, a LTR comprises or consists of a nucleotide sequence that has at least 70% sequence identity to SEQ ID NO: 15 or a fragment thereof. Suitably, a LTR comprises or consists of a nucleotide sequence that has at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 15 or a fragment thereof. In some embodiments, a LTR comprises or consists of the nucleotide sequence SEQ ID NO: 15 or a fragment thereof. TGGAAGGGCTAATTCACTCCCAACGAAGACAAGATCTGCTTTTTGCTTGTACTGGGTCTCTCTGGTTA GACCAGATCTGAGCCTGGGAGCTCTCTGGCTAACTAGGGAACCCACTGCTTAAGCCTCAATAAAGCTT GCCTTGAGTGCTTCAAGTAGTGTGTGCCCGTCTGTTGTGTGACTCTGGTAACTAGAGATCCCTCAGAC CCTTTTAGTCAGTGTGGAAAATCTCTAGCAG (SEQ ID NO: 15) The vector (e.g. lentiviral vector) of the invention may comprise one or more self-inactivating long terminal repeat (SIN-LTR). A “SIN-LTR” may comprise a deletion that abolishes transcription of the full-length virus after it has incorporated into a host cell. For example, a 3’ SIN-LTR may comprise a deletion in the U3 region removing the promoter / enhancer elements (see, for example, Zufferey et al. (1998) Journal of Virology 72: 9873-9880). This deletion is copied into the 5’ LTR after reverse transcription, thereby making the gene expression in target cells dependent on an internal promoter of choice. Suitable SIN-LTR sequences will be well known to the skilled person (see, for example, Zufferey et al. (1998) Journal of Virology 72: 9873-9880; Miyoshi et al. (1998) Journal of Virology 72: 8150-8157). In some embodiments, the 5’ LTR comprises or consists of a nucleotide sequence that has at least 70% sequence identity to SEQ ID NO: 16 or a fragment thereof. Suitably, the 5’ LTR comprises or consists of a nucleotide sequence that has at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 16 or a fragment thereof. In some embodiments, the 5’ LTR comprises or consists of the nucleotide sequence SEQ ID NO: 16 or a fragment thereof. GGGTCTCTCTGGTTAGACCAGATCTGAGCCTGGGAGCTCTCTGGCTAACTAGGGAACCCACTGCTTAA GCCTCAATAAAGCTTGCCTTGAGTGCTTCAAGTAGTGTGTGCCCGTCTGTTGTGTGACTCTGGTAACT AGAGATCCCTCAGACCCTTTTAGTCAGTGTGGAAAATCTCTAGCAG (SEQ ID NO: 16) In some embodiments, the 5’ LTR and / or the 3’ LTR comprises or consists of a nucleotide sequence that has at least 70% sequence identity to SEQ ID NO: 15 or a fragment thereof. Suitably, the 5’ LTR and / or the 3’ LTR comprises or consists of a nucleotide sequence that has at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 15 or a fragment thereof. In some embodiments, the 5’ LTR and / or the 3’ LTR comprises or consists of the nucleotide sequence SEQ ID NO: 15 or a fragment thereof. In some embodiments, the 5’ LTR and the 3’ LTR comprise or consist of a nucleotide sequence that has at least 70% sequence identity to SEQ ID NO: 15 or a fragment thereof. Suitably, the 5’ LTR and the 3’ LTR comprise or consist of a nucleotide sequence that has at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 15 or a fragment thereof. In some embodiments, the 5’ LTR and the 3’ LTR comprise or consist of the nucleotide sequence SEQ ID NO: 15 or a fragment thereof. Primer binding site (PBS) The vector (e.g. lentiviral vector) of the invention may comprise a primer binding site (PBS). A PBS is a cis-acting element where a primer may bind to initiate reverse transcription of the RNA genome (see, for example, Lanchy et al. (1998) Journal of Biological Chemistry 273: 24425-24432). Suitable retroviral PBSs will be well known to the skilled person. In some embodiments, a PBS comprises or consists of a nucleotide sequence that has at least 70% sequence identity to SEQ ID NO: 17 or a fragment thereof. Suitably, a PBS comprises or consists of a nucleotide sequence that has at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to SEQ ID NO: 17 or a fragment thereof. In some embodiments, a PBS comprises or consists of the nucleotide sequence SEQ ID NO: 17 or a fragment thereof. TGGCGCCCGAACAGGGACTTGAAAGCGAAAGGGAAACCAGAGGAGCTCTCTCGACGCAGGACTCGGCT TGCTGAAGCGCGCACGGCAAGAGGCGAGGGGCGGCGACTGGTGAGTACGCCAAAAATTTTGACTAGCG GAGGCTAGAAGGAGAGAG Retroviral psi packaging element The vector (e.g. lentiviral vector) of the invention may comprise a retroviral psi packaging element. A retroviral psi packaging element is a cis-acting element which is involved in regulating the process of packaging the retroviral RNA genome into the viral capsid during replication (see, for example, McBride et al. (1997) Journal of Virology 71: 4544-4554). A retroviral psi packaging element may form part of the 5’ region of the gag gene. Suitable retroviral psi packaging elements will be well known to the skilled person. In some embodiments, a retroviral psi packaging element comprises or consists of a nucleotide sequence that has at least 70% sequence identity to SEQ ID NO: 18 or a fragment thereof. Suitably, a retroviral psi packaging element comprises or consists of a nucleotide sequence that has at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 18 or a fragment thereof. In some embodiments, a retroviral psi packaging element comprises or consists of the nucleotide sequence SEQ ID NO: 18 or a fragment thereof. ATGGGTGCGAGAGCGTCAGTATTAAGCGGGGGAGAATTAGATCGCGATGGGAAAAAATTCGGTTAAGG CCAGGGGGAAAGAAAAAATATAAATTAAAACATATAGTATGGGCAAGCAGGGAGCTAGAACGATTCGC AGTTAATCCTGGCCTGTTAGAAACATCAGAAGGCTGTAGACAAATACTGGGACAGCTACAACCATCCC TTCAGACAGGATCAGAAGAACTTAGATCATTATATAATACAGTAGCAACCCTCTATTGTGTGCATCAA AGGATAGAGATAAAAGACACCAAGGAAGCTTTAGACAAGATAGAGGAAGAGCAAAACAAAAGTAAGAC CACCGCACAGCAAGCGGCCGCTGAT (SEQ ID NO: 18) Rev response element (RRE) The vector (e.g. lentiviral vector) of the invention may comprise a rev response element (RRE). A RRE is a cis-acting element that enables the efficient export of RNA transcripts of the integrated provirus from the nucleus to the cytoplasm of an infected target cell (see, for example, Pollard et al. (1998) Annual Review of Microbiology 52: 491-532). Suitable RRE sequences will be well known to the skilled person. In some embodiments, a RRE comprises or consists of a nucleotide sequence that has at least 70% sequence identity to SEQ ID NO: 19 or a fragment thereof. Suitably, a RRE i i t f l tid th t h t l t 75% t l t 80% t l t 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to SEQ ID NO: 19 or a fragment thereof. In some embodiments, a RRE comprises or consists of the nucleotide sequence SEQ ID NO: 19 or a fragment thereof. GGAGCTTTGTTCCTTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGCGCAGCGTCAATGACGCTGAC GGTACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAATTTGCTGAGGGCTATTGAGG CGCAACAGCATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAGCTCCAGGCAAGAATCCTGGCTGTG GAAAGATACCTAAAGGATCAACAGCTCCTGGGGATTT (SEQ ID NO: 19) Central polypurine tract (cPPT) The vector (e.g. lentiviral vector) of the invention may comprise a central polypurine tract (cPPT). A cPPT may allow initiation of plus-strand synthesis (see, for example, Follenzi et al. (2000) Nature Genetics 25: 217-222). Suitable cPPT sequences will be well known to the skilled person. In some embodiments, a cPPT comprises or consists of a nucleotide sequence that has at least 70% sequence identity to SEQ ID NO: 20 or a fragment thereof. Suitably, a cPPT comprises or consists of a nucleotide sequence that has at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 20 or a fragment thereof. In some embodiments, a cPPT comprises or consists of the nucleotide sequence SEQ ID NO: 20 or a fragment thereof. AACTTTTAAAAGAAAAGGGGGGATTGGGGGGTACAGTGCAGGGGAAAGAATAGTAGACATAATAGCAA CAGACATACAAACTAAAGAATTACAAAAACAAATTACAAAAATTCAAAATTTTATC (SEQ ID NO: 20) INTERLEUKIN-10 (IL-10) The vector of the invention comprises a transgene encoding interleukin 10 (IL-10). Interleukin 10 (IL-10) is a cytokine produced by a variety of immune cells, including T cells, B cells, and macrophages, as well as non-immune cells, such as astrocytes and neurons. It serves as a potent antiinflammatory mediator by suppressing the expression of pro inflammatory cytokines, such as IL-1, IL-6 and TNFα, and promoting the expression of anti- inflammatory cytokines, such as IL-1 receptor antagonist (IL-1Ra) and IL-10 itself. Additionally, IL-10 has profound impact on microglia behaviour toward a phagocytic phenotype. In some embodiments, the IL-10 is human IL-10. An exemplary Interleukin-10 amino acid sequence is: MHSSALLCCLVLLTGVRASPGQGTQSENSCTHFPGNLPNMLRDLRDAFSRVKTFFQMKDQLDNLLLKE SLLEDFKGYLGCQALSEMIQFYLEEVMPQAENQDPDIKAHVNSLGENLKTLRLRLRRCHRFLPCENKS KAVEQVKNAFNKLQEKGIYKAMSEFDIFINYIEAYMTMKIRN (SEQ ID NO: 8) In some embodiments, the IL-10 comprises or consists of an amino acid sequence that has at least 70% sequence identity to SEQ ID NO: 8 or a fragment thereof. Suitably, the IL-10 comprises or consists of an amino acid sequence that has at least 75%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 8 or a fragment thereof. In some embodiments, the IL-10 comprises or consists of the amino acid sequence of SEQ ID NO: 8 or a fragment thereof. A fragment and / or variant of IL-10 may retain IL-10 activity (e.g. the activity of SEQ ID NO: 8). For example, a fragment and / or variant of IL-10 may act as an anti-inflammatory mediator by suppressing the expression of pro-inflammatory cytokines, such as IL-1, IL-6 and TNFα, and / or promoting the expression of anti-inflammatory cytokines, such as IL-1 receptor antagonist (IL-1Ra) and IL-10. Suitably, a fragment and / or variant of IL-10 may have the same or similar activity to IL-10, for example may have at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% or 100% of the activity of IL-10 (e.g. the IL-10 of SEQ ID NO: 8). The skilled person will be able to generate fragments and / or variants, for example using conservative substitutions, based on the known structural and functional features of IL-10. In some embodiments, the transgene encoding IL-10 comprises or consists of a nucleotide sequence encoding an amino acid sequence that has at least 70%, 80%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO: 8. In some embodiments, the transgene encoding IL-10 comprises or consists of a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 8. An exemplary nucleotide sequence encoding Interleukin-10 is: ATGCACAGCTCAGCACTGCTCTGTTGCCTGGTCCTCCTGACTGGGGTGAGGGCCAGCCCAGGCCAGGG CACCCAGTCTGAGAACAGCTGCACCCACTTCCCAGGCAACCTGCCTAACATGCTTCGAGATCTCCGAG ATGCCTTCAGCAGAGTGAAGACTTTCTTTCAAATGAAGGATCAGCTGGACAACTTGTTGTTAAAGGAG TCCTTGCTGGAGGACTTTAAGGGTTACCTGGGTTGCCAAGCCTTGTCTGAGATGATCCAGTTTTACCT GGAGGAGGTGATGCCCCAAGCTGAGAACCAAGACCCAGACATCAAGGCGCATGTGAACTCCCTGGGGG AGAACCTGAAGACCCTCAGGCTGAGGCTACGGCGCTGTCATCGATTTCTTCCCTGTGAAAACAAGAGC AAGGCCGTGGAGCAGGTGAAGAATGCCTTTAATAAGCTCCAAGAGAAAGGCATCTACAAAGCCATGAG TGAGTTTGACATCTTCATCAACTACATAGAAGCCTACATGACAATGAAGATACGAAAC (SEQ ID NO: 9) In some embodiments, the transgene encoding IL-10 comprises or consists of a nucleotide sequence that has at least 70%, 80%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO: 9. In some embodiments, the transgene encoding IL-10 comprises or consists of SEQ ID NO: 9. VECTORS A vector is a tool that allows or facilitates the transfer of an entity from one environment to another. In accordance with the invention, and by way of example, some vectors used in recombinant nucleic acid techniques allow entities, such as a segment of nucleic acid (e.g. a heterologous DNA segment, such as a heterologous cDNA segment), to be transferred into a target cell. The vector may serve the purpose of maintaining the heterologous nucleic acid (DNA or RNA) within the cell, facilitating the replication of the vector comprising a segment of nucleic acid and / or facilitating the expression of the protein encoded by a segment of nucleic acid. Vectors may include a promoter for the expression of a polynucleotide and optionally a regulator of the promoter. Vectors comprising polynucleotides may be introduced into cells using a variety of techniques known in the art, such as transfection, transduction and transformation. Transfection may refer to a general process of incorporating a nucleic acid into a cell and includes a process using a non-viral vector to deliver a polynucleotide to a cell. Transduction may refer to a process of incorporating a nucleic acid into a cell using a viral vector. Suitably, the vector of the invention is a viral vector. The vector of the invention may be a lentiviral vector, although it is contemplated that other viral vectors may be used. Other suitable viral vectors include those described in Lundstrom, et al. (2018) Diseases 6: 42. For example, other suitable viral vectors include a retroviral vector, an adenoviral vector, an adeno-associated viral vector, a herpes simplex viral vector, an alphaviral vector, a flaviviral vector, a rhabdoviral vector, a measles viral vector, a Newcastle disease viral vector, a poxviral vector and a picornaviral vector. The vector of the invention may be in the form of a viral vector particle. Suitably, the viral vector of the invention is in the form of a lentiviral vector particle. The vector may be an integrating viral vector or a non-integrating viral vector. An “integrating viral vector” is capable of integrating into the host cell genome following transduction into the host cell. A “non-integrating viral vector” is not capable of integrating into the host cell genome following transduction into the host cell or demonstrates very weak integration capability. Methods of preparing and modifying viral vectors and viral vector particles, such as lentiviral vectors, are well known in the art. Retroviral and lentiviral vectors The vector of the invention may, for example, be a retroviral vector or a lentiviral vector. The vector of the invention may, for example, be a retroviral vector particle or a lentiviral vector particle. A retroviral vector may be derived from or may be derivable from any suitable retrovirus. A large number of different retroviruses have been identified. Examples include murine leukaemia virus (MLV), human T-cell leukaemia virus (HTLV), mouse mammary tumour virus (MMTV), Rous sarcoma virus (RSV), Fujinami sarcoma virus (FuSV), Moloney murine leukaemia virus (Mo-MLV), FBR murine osteosarcoma virus (FBR MSV), Moloney murine sarcoma virus (Mo-MSV), Abelson murine leukaemia virus (A-MLV), avian myelocytomatosis virus-29 (MC29) and avian erythroblastosis virus (AEV). Retroviruses may be broadly divided into two categories, “simple” and “complex”. Retroviruses may be even further divided into seven groups. Five of these groups represent retroviruses with oncogenic potential. The remaining two groups are the lentiviruses and the spumaviruses. The basic structure of retrovirus and lentivirus genomes share many common features such as a 5’ LTR and a 3’ LTR. Between or within these are located a packaging signal to enable the genome to be packaged, a primer binding site, integration sites to enable integration into a host cell genome, and gag, pol and env genes encoding the packaging components – these are polypeptides required for the assembly of viral particles. Lentiviruses have additional features, such as rev and RRE sequences in HIV, which enable the efficient export of RNA transcripts of the integrated provirus from the nucleus to the cytoplasm of an infected target cell. In the provirus, these genes are flanked at both ends by regions called long terminal repeats (LTRs). The LTRs are responsible for proviral integration and transcription. LTRs also serve as enhancer-promoter sequences and can control the expression of the viral genes. The LTRs themselves are identical sequences that can be divided into three elements: U3, R and U5. U3 is derived from the sequence unique to the 3’ end of the RNA. R is derived from a sequence repeated at both ends of the RNA. U5 is derived from the sequence unique to the 5’ end of the RNA. The sizes of the three elements can vary considerably among different retroviruses. In a defective retroviral vector genome gag, pol and env may be absent or not functional. In a typical retroviral vector, at least part of one or more protein coding regions essential for replication may be removed from the virus. This makes the viral vector replication-defective. Portions of the viral genome may also be replaced by a library encoding candidate modulating moieties operably linked to a regulatory control region and a reporter moiety in the vector genome in order to generate a vector comprising candidate modulating moieties which is capable of transducing a target host cell and / or integrating its genome into a host genome. Lentivirus vectors are part of the larger group of retroviral vectors. In brief, lentiviruses can be divided into primate and non-primate groups. Examples of primate lentiviruses include but are not limited to human immunodeficiency virus (HIV), the causative agent of human acquired immunodeficiency syndrome (AIDS); and simian immunodeficiency virus (SIV). Examples of non-primate lentiviruses include the prototype “slow virus” visna / maedi virus (VMV), as well as the related caprine arthritis-encephalitis virus (CAEV), equine infectious anaemia virus (EIAV), and the more recently described feline immunodeficiency virus (FIV) and bovine immunodeficiency virus (BIV). The lentivirus family differs from retroviruses in that lentiviruses have the capability to infect both dividing and non-dividing cells. In contrast, other retroviruses, such as MLV, are unable to infect non-dividing or slowly dividing cells such as those that make up, for example, muscle, brain lung and liver tissue A “lentiviral vector”, as used herein, is a vector which comprises at least one component part derivable from a lentivirus. Suitably, that component part is involved in the biological mechanisms by which the vector infects cells, expresses genes or is replicated. The lentiviral vector may be a “primate” vector. The lentiviral vector may be a “non-primate” vector (i.e. derived from a virus which does not primarily infect primates, especially humans). Examples of non-primate lentiviruses may be any member of the family of lentiviridae which does not naturally infect a primate. As examples of lentivirus-based vectors, HIV-1- and HIV-2-based vectors are described below. The HIV-1 vector contains cis-acting elements that are also found in simple retroviruses. It has been shown that sequences that extend into the gag open reading frame are important for packaging of HIV-1. Therefore, HIV-1 vectors often contain the relevant portion of gag in which the translational initiation codon has been mutated. In addition, most HIV-1 vectors also contain a portion of the env gene that includes the RRE. Rev binds to RRE, which permits the transport of full-length or singly spliced mRNAs from the nucleus to the cytoplasm. In the absence of Rev and / or RRE, full-length HIV-1 RNAs accumulate in the nucleus. Alternatively, a constitutive transport element from certain simple retroviruses such as Mason-Pfizer monkey virus can be used to relieve the requirement for Rev and RRE. Efficient transcription from the HIV-1 LTR promoter requires the viral protein Tat. Most HIV-2-based vectors are structurally very similar to HIV-1 vectors. Similar to HIV-1-based vectors, HIV-2 vectors also require RRE for efficient transport of the full-length or singly spliced viral RNAs. Optionally, the viral vector used in the invention has a minimal viral genome. By “minimal viral genome” it is to be understood that the viral vector has been manipulated so as to remove the non-essential elements and to retain the essential elements in order to provide the required functionality to infect, transduce and deliver a nucleotide sequence of interest to a target host cell. Further details of this strategy can be found in WO 1998 / 017815. Optionally, the plasmid vector used to produce the viral genome within a host cell / packaging cell will have sufficient lentiviral genetic information to allow packaging of an RNA genome, in the presence of packaging components, into a viral particle which is capable of infecting a target cell, but is incapable of independent replication to produce infectious viral particles within the final target cell. Optionally, the vector lacks a functional gag-pol and / or env gene However, the plasmid vector used to produce the viral genome within a host cell / packaging cell will also include transcriptional regulatory control sequences operably linked to the lentiviral genome to direct transcription of the genome in a host cell / packaging cell. These regulatory sequences may be the natural sequences associated with the transcribed viral sequence (i.e. the 5’ U3 region), or they may be a heterologous promoter, such as another viral promoter (e.g. the CMV promoter). The vectors may be self-inactivating (SIN) vectors in which the viral enhancer and promoter sequences have been deleted. SIN vectors can be generated and transduce non-dividing cells in vivo with an efficacy similar to that of wild-type vectors. The transcriptional inactivation of the long terminal repeat (LTR) in the SIN provirus should prevent mobilisation by replication- competent virus. This should also enable the regulated expression of genes from internal promoters by eliminating any cis-acting effects of the LTR. The vector may be integration-defective. Integration defective lentiviral vectors can be produced, for example, either by packaging the vector with catalytically inactive integrase (such as an HIV integrase bearing the D64V mutation in the catalytic site) or by modifying or deleting essential att sequences from the vector LTR, or by a combination of the above. In some embodiments, the vector is an integration-defective lentiviral vector. In some embodiments, the vector is an integration-proficient lentiviral vector. Suitably, the vector is VSV-G-pseudotyped. In some embodiments, the vector is a VSV-G- pseudotyped lentiviral vector particle. Adeno-associated virus (AAV) In one aspect, the vector is an adeno-associated viral (AAV) vector. In one aspect, the vector is an adeno-associated viral (AAV) vector particle. The use of AAV as a vector may be an alternative to the use of a lentiviral vector comprising the one or more miRNA target sequence. For example, the AAV vector may lack miRNA target sequences. The AAV vector may be of a serotype for astrocyte-specific expression and / or may comprise an astrocyte-specific promoter. Methods of preparing and modifying viral vectors and viral vector particles, such as those derived from AAV, are well known in the art. The AAV particle may comprise an AAV genome or a fragment or derivative thereof. An AAV genome is a polynucleotide sequence, which may encode functions needed for production of an AAV particle. These functions include those operating in the replication and packaging cycle of AAV in a host cell, including encapsidation of the AAV genome into an AAV particle. Naturally occurring AAVs are replication-deficient and rely on the provision of helper functions in trans for completion of a replication and packaging cycle. Accordingly, the AAV genome of the AAV vector of the invention is typically replication-deficient. The AAV genome may be in single-stranded form, either positive or negative-sense, or alternatively in double-stranded form. The use of a double-stranded form allows bypass of the DNA replication step in the target cell and so can accelerate transgene expression. The AAV genome may be from any naturally derived serotype, isolate or clade of AAV. Thus, the AAV genome may be the full genome of a naturally occurring AAV. As is known to the skilled person, AAVs occurring in nature may be classified according to various biological systems. Commonly, AAVs are referred to in terms of their serotype. A serotype corresponds to a variant subspecies of AAV which, owing to its profile of expression of capsid surface antigens, has a distinctive reactivity which can be used to distinguish it from other variant subspecies. Typically, a virus having a particular AAV serotype does not efficiently cross-react with neutralising antibodies specific for any other AAV serotype. AAV serotypes include AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10 and AAV11, and also recombinant serotypes, such as Rec2 and Rec3, recently identified from primate brain. In some embodiments, the AAV is AAV1, AAV6, AAV6.2, AAV7, AAV9, rh10, rh39 or rh43. In some embodiments, the AAV comprises a capsid protein derived from an AAV1, AAV6, AAV6.2, AAV7, AAV9, rh10, rh39 or rh43 capsid protein. Reviews of AAV serotypes may be found in Choi et al. (2005) Curr. Gene Ther.5: 299-310 and Wu et al. (2006) Molecular Therapy 14: 316-27. The sequences of AAV genomes or of elements of AAV genomes including ITR sequences, rep or cap genes may be derived from the following accession numbers for AAV whole genome sequences: Adeno-associated virus 1 NC_002077, AF063497; Adeno-associated virus 2 NC_001401; Adeno-associated virus 3 NC_001729; Adeno-associated virus 3B NC_001863; Adeno-associated virus 4 NC_001829; Adeno-associated virus 5 Y18065, AF085716; Adeno-associated virus 6 NC_001862; Avian AAV ATCC VR-865 AY186198, AY629583, NC_004828; Avian AAV strain DA-1 NC_006263, AY629583; Bovine AAV NC 005889 AY388617 AAV capsid protein In one aspect, the AAV vector particle comprises an AAV capsid protein, wherein the capsid protein comprises a peptide comprising or consisting of the amino acid sequence PGVPGRF (SEQ ID NO: 21), or a variant thereof having up to two amino acid substitutions, additions or deletions. In one aspect, the AAV vector particle comprises an AAV capsid protein, wherein the capsid protein comprises a peptide comprising or consisting of the amino acid sequence AGPGVPGRF (SEQ ID NO: 22), or a variant thereof having up to two amino acid substitutions, additions or deletions. In one aspect, the AAV vector particle comprises an AAV capsid protein, wherein the capsid protein comprises a peptide comprising or consisting of the amino acid sequence NGVRSVG (SEQ ID NO: 23), or a variant thereof having up to two amino acid substitutions, additions or deletions. In one aspect, the AAV vector particle comprises an AAV capsid protein, wherein the capsid protein comprises a peptide comprising or consisting of the amino acid sequence AGNGVRSVG (SEQ ID NO: 24), or a variant thereof having up to two amino acid substitutions, additions or deletions. In some embodiments, the AAV capsid protein is an AAV VP1 capsid protein. In some embodiments, the AAV is AAV1, AAV6, AAV6.2, AAV7, AAV9, rh10, rh39 or rh43. In some embodiments, the AAV is AAV9. An example wild type AAV9 capsid protein amino acid sequence is: MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAA DAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAA KTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPDPQPIGEPPAAPSGVGSLTMA SGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDN AYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTS TVQVFTDSDYQLPYVLGSAHEGCLPPFPADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTG NNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGR NYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFG KQGTGRDNVDADKVMITNEEEIKTTNPVATESYGQVATNHQSAQAQAQTGWVQNQGILPGMVWQDRDV YLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVS VEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL (SEQ ID NO: 25) In some embodiments, the peptide is positioned immediately after a position corresponding to amino acid 588 of SEQ ID NO: 25. The terms “corresponding to”, “reference to” and “relative to” when used in the context of the numbering of a given amino acid or polynucleotide sequence may refer to the numbering of the residues of a specified reference sequence when the given amino acid or polynucleotide sequence is compared to the reference sequence. In other words, the residue number or residue position of a given polymer is designated with respect to the reference sequence rather than by the actual numerical position of the residue within the given amino acid or polynucleotide sequence. For example, a given amino acid sequence, such as that of an AAV capsid protein, can be aligned to a reference sequence by introducing gaps to optimise residue matches between the two sequences. In these cases, although the gaps are present, the numbering of the residue in the given amino acid or polynucleotide sequence is made with respect to the reference sequence to which it has been aligned. Example AAV capsid sequences that comprise the peptide of the disclosure are: MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAA DAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAA KTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPDPQPIGEPPAAPSGVGSLTMA SGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDN AYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTS TVQVFTDSDYQLPYVLGSAHEGCLPPFPADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTG NNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGR NYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFG KQGTGRDNVDADKVMITNEEEIKTTNPVATESYGQVATNHQSAQPGVPGRFAQAQTGWVQNQGILPGM VWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQ YSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL (SEQ ID NO: 26) MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAA DAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAA KTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPDPQPIGEPPAAPSGVGSLTMA SGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDN AYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTS TVQVFTDSDYQLPYVLGSAHEGCLPPFPADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTG NNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGR KQGTGRDNVDADKVMITNEEEIKTTNPVATESYGQVATNHQSAQAGPGVPGRFAQAQTGWVQNQGILP GMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFI TQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL (SEQ ID NO: 27) MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAA DAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAA KTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPDPQPIGEPPAAPSGVGSLTMA SGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDN AYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTS TVQVFTDSDYQLPYVLGSAHEGCLPPFPADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTG NNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGR NYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFG KQGTGRDNVDADKVMITNEEEIKTTNPVATESYGQVATNHQSAQNGVRSVGAQAQTGWVQNQGILPGM VWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQ YSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL (SEQ ID NO: 28) MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAA DAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAA KTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPDPQPIGEPPAAPSGVGSLTMA SGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDN AYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTS TVQVFTDSDYQLPYVLGSAHEGCLPPFPADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTG NNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGR NYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFG KQGTGRDNVDADKVMITNEEEIKTTNPVATESYGQVATNHQSAQAGNGVRSVGAQAQTGWVQNQGILP GMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFI TQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL (SEQ ID NO: 29) In some embodiments, the AAV vector particle comprises an AAV capsid protein, wherein the capsid protein comprises or consists of an amino acid sequence that has at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO: 26. In some embodiments, the AAV vector particle comprises an AAV capsid protein, wherein the capsid protein comprises or consists of an amino acid sequence that has at least 75%, 80%, 85%, In some embodiments, the capsid protein comprises or consists of the amino acid sequence of SEQ ID NO: 26. In some embodiments, the capsid protein comprises or consists of the amino acid sequence of SEQ ID NO: 27. In some embodiments, the AAV vector particle comprises an AAV capsid protein, wherein the capsid protein comprises or consists of an amino acid sequence that has at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO: 28. In some embodiments, the AAV vector particle comprises an AAV capsid protein, wherein the capsid protein comprises or consists of an amino acid sequence that has at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO: 29. In some embodiments, the capsid protein comprises or consists of the amino acid sequence of SEQ ID NO: 28. In some embodiments, the capsid protein comprises or consists of the amino acid sequence of SEQ ID NO: 29. In some embodiments, the AAV vector particle comprises an AAV capsid protein, wherein the capsid protein further comprises the mutation A587G, wherein the amino acids are numbered with reference to SEQ ID NO: 25. In some embodiments, the AAV vector particle comprises an AAV capsid protein, wherein the capsid protein further comprises the mutation Q592A, wherein the amino acids are numbered with reference to SEQ ID NO: 25. In some embodiments, the AAV vector particle comprises an AAV capsid protein, wherein the capsid protein further comprises the mutations A587G and Q592A, wherein the amino acids are numbered with reference to SEQ ID NO: 25. In some embodiments, the AAV vector particle comprises an AAV capsid protein, wherein the capsid protein further comprises the mutation W503A, wherein the amino acids are numbered with reference to SEQ ID NO: 25. In some embodiments, the AAV vector particle comprises an AAV capsid protein, wherein the capsid protein further comprises the mutations A587G and W503A, wherein the amino acids are numbered with reference to SEQ ID NO: 25. In some embodiments, the AAV vector particle comprises an AAV capsid protein, wherein the capsid protein further comprises the mutations Q592A and W503A, wherein the amino acids are numbered with reference to SEQ ID NO: 25. In some embodiments, the AAV vector particle comprises an AAV capsid protein, wherein the capsid protein further comprises the mutations A587G, Q592A and W503A, wherein the amino acids are numbered with reference to SEQ ID NO: 25. In some embodiments, the AAV vector particle comprises an AAV capsid protein, wherein the capsid protein further comprises the mutation K449R, wherein the amino acids are numbered with reference to SEQ ID NO: 25. In some embodiments, the AAV vector particle comprises an AAV capsid protein, wherein the capsid protein further comprises the mutations A587G, Q592A, W503A and K449R, wherein the amino acids are numbered with reference to SEQ ID NO: 25. Example AAV capsid proteins of the invention are: MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAA DAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAA KTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPDPQPIGEPPAAPSGVGSLTMA SGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDN AYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTS TVQVFTDSDYQLPYVLGSAHEGCLPPFPADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTG NNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSRTINGSGQNQQTLKFSVAGPSNMAVQGR NYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFG KQGTGRDNVDADKVMITNEEEIKTTNPVATESYGQVATNHQSGQAGPGVPGRFAQAATGWVQNQGILP GMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFI TQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL (SEQ ID NO: 30 – Se2) MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAA DAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAA KTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPDPQPIGEPPAAPSGVGSLTMA SGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDN AYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTS TVQVFTDSDYQLPYVLGSAHEGCLPPFPADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTG NNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGR NYIPGPSYRQQRVSTTVTQNNNSEFAAPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFG KQGTGRDNVDADKVMITNEEEIKTTNPVATESYGQVATNHQSGQAGNGVRSVGAQAATGWVQNQGILP GMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFI TQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL (SEQ ID NO: 31 – Se1) In some embodiments, the AAV vector particle comprises an AAV capsid protein, wherein the capsid protein comprises or consists of an amino acid sequence that has at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO: 30. In some embodiments, the AAV vector particle comprises an AAV capsid protein, wherein the capsid protein comprises or consists of the amino acid sequence of SEQ ID NO: 30. In some embodiments, the AAV vector particle comprises an AAV capsid protein, wherein the capsid protein comprises or consists of an amino acid sequence that has at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO: 31. In some embodiments, the AAV vector particle comprises an AAV capsid protein, wherein the capsid protein comprises or consists of the amino acid sequence of SEQ ID NO: 31. ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGAATTCGCGAGTGGTG GGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTG TGCTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCA GACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCT CAAGTACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGCAACC TCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCT AAGACGGCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTAT TGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAG TCCCAGACCCTCAACCAATCGGAGAACCTCCCGCAGCCCCCTCAGGTGTGGGATCTCTTACAATGGCT TCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAA TTGGCATTGCGATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGC CCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAAC GCCTACTTCGGCTACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACC ACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCT TCAACATTCAGGTCAAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGC ACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTG CCTCCCGCCGTTCCCAGCGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAA GCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGT AACAACTTCCAGTTCAGCTACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAG CCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCTAGAACTATTAACGGTT CTGGACAGAATCAACAAACGCTAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGA AACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAG CGAATTTGCTTGGCCTGGAGCTTCTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGAC CTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGC AACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACAAACCACCAGAGTGGCCAAGCAG GCCCTGGTGTTCCGGGGCGGTTTGCCCAGGCGGCCACCGGTTGGGTTCAAAACCAAGGAATACTTCCG GGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGA CGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCCTCAGATCCTCA TCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATC ACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAACAGCAAGCG CTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATA CTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA (SEQ ID NO: 32 – Se2) ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGAATTCGCGAGTGGTG GGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTG TGCTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCA GACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCT CAAGTACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGCAACC TCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCT AAGACGGCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTAT TGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAG TCCCAGACCCTCAACCAATCGGAGAACCTCCCGCAGCCCCCTCAGGTGTGGGATCTCTTACAATGGCT TCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAA TTGGCATTGCGATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGC CCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAAC GCCTACTTCGGCTACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACC ACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCT TCAACATTCAGGTCAAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGC ACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTG CCTCCCGCCGTTCCCAGCGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAA GCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGT AACAACTTCCAGTTCAGCTACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAG CCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTT CTGGACAGAATCAACAAACGCTAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGA AACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAG CGAATTTGCTGCGCCTGGAGCTTCTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGAC CTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGC AAACAAGGAACTGGAAGAGACAACGTGGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAA AACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACAAACCACCAGAGTGGCCAAGCAG GGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGA CGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCCTCAGATCCTCA TCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATC ACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAACAGCAAGCG CTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATA CTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA (SEQ ID NO: 33 – Se1) In some embodiments, the AAV vector particle comprises an AAV capsid protein, wherein the capsid protein is encoded by a nucleotide sequence that has at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO: 32. In some embodiments, the AAV vector particle comprises an AAV capsid protein, wherein the capsid protein is encoded by the nucleotide sequence of SEQ ID NO: 32. In some embodiments, the AAV vector particle comprises an AAV capsid protein, wherein the capsid protein is encoded by a nucleotide sequence that has at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO: 33. In some embodiments, the AAV vector particle comprises an AAV capsid protein, wherein the capsid protein is encoded by the nucleotide sequence of SEQ ID NO: 33. AAV genomes Typically, the AAV genome of a naturally derived serotype, isolate or clade of AAV comprises at least one inverted terminal repeat sequence (ITR). An ITR sequence acts in cis to provide a functional origin of replication and allows for integration and excision of the vector from the genome of a cell. The AAV genome may also comprise packaging genes, such as rep and / or cap genes which encode packaging functions for an AAV particle. The rep gene encodes one or more of the proteins Rep78, Rep68, Rep52 and Rep40 or variants thereof. The cap gene encodes one or more capsid proteins such as VP1, VP2 and VP3 or variants thereof. These proteins make up the capsid of an AAV particle. A promoter may be operably linked to each of the packaging genes. Specific examples of such promoters include the p5, p19 and p40 promoters (Laughlin et al. (1979) Proc. Natl. Acad. Sci. USA 76: 5567-5571). For example, the p5 and p19 promoters are generally used to express the rep gene, while the p40 promoter is generally used to express the cap gene. The AAV genome used in the AAV vector of the invention may therefore be the full genome used to prepare an AAV vector or vector particle in vitro. However, while such a vector may in principle be administered to patients, this will rarely be done in practice. Preferably, the AAV genome will be derivatised for the purpose of administration to patients. Such derivatisation is standard in the art and the invention encompasses the use of any known derivative of an AAV genome, and derivatives which could be generated by applying techniques known in the art. Derivatisation of the AAV genome and of the AAV capsid are reviewed in Coura and Nardi (2007) Virology Journal 4: 99, and in Choi et al. and Wu et al., referenced above. Derivatives of an AAV genome include any truncated or modified forms of an AAV genome which allow for expression of a transgene from an AAV in vivo. Typically, it is possible to truncate the AAV genome significantly to include minimal viral sequence yet retain the above function. This is preferred for safety reasons to reduce the risk of recombination of the vector with wild-type virus, and also to avoid triggering a cellular immune response by the presence of viral gene proteins in the target cell. Typically, a derivative will include at least one inverted terminal repeat sequence (ITR), preferably more than one ITR, such as two ITRs or more. One or more of the ITRs may be derived from AAV genomes having different serotypes, or may be a chimeric or mutant ITR. A preferred mutant ITR is one having a deletion of a trs (terminal resolution site). This deletion allows for continued replication of the genome to generate a single-stranded genome which contains both coding and complementary sequences, i.e. a self-complementary AAV genome. This allows for bypass of DNA replication in the target cell, and so enables accelerated transgene expression. In some embodiments, the AAV comprises at least one, such as two, AAV serotype 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11 ITRs. Preferably, the AAV comprises at least one, such as two, AAV serotype 2 ITRs. The one or more ITRs will preferably flank the nucleotide sequence of interest (which may also be referred to as a transgene) at either end. The inclusion of one or more ITRs is preferred to aid concatamer formation in the nucleus of a host cell, for example following the conversion of single-stranded vector DNA into double-stranded DNA by the action of host cell DNA polymerases. The formation of such episomal concatamers protects the vector construct during the life of the host cell, thereby allowing for prolonged expression of the transgene in vivo. In preferred embodiments, ITR elements will be the only sequences retained from the native AAV genome in the derivative. Thus, a derivative will preferably not include the rep and / or cap for the reasons described above, and also to reduce the possibility of integration of the vector into the host cell genome. Additionally, reducing the size of the AAV genome allows for increased flexibility in incorporating other sequence elements (such as regulatory elements) within the vector in addition to the transgene. The following portions could therefore be removed in a derivative of the invention: one inverted terminal repeat (ITR) sequence, the replication (rep) and capsid (cap) genes. However, in some embodiments, derivatives may additionally include one or more rep and / or cap genes or other viral sequences of an AAV genome. Naturally occurring AAV integrates with a high frequency at a specific site on human chromosome 19, and shows a negligible frequency of random integration, such that retention of an integrative capacity in the vector may be tolerated in a therapeutic setting. The invention additionally encompasses the provision of sequences of an AAV genome in a different order and configuration to that of a native AAV genome. The invention also encompasses the replacement of one or more AAV sequences or genes with sequences from another virus or with chimeric genes composed of sequences from more than one virus. Such chimeric genes may be composed of sequences from two or more related viral proteins of different viral species. The AAV particles of the invention include transcapsidated forms wherein an AAV genome or derivative having an ITR of one serotype is packaged in the capsid of a different serotype. The AAV particles of the invention also include mosaic forms wherein a mixture of capsid proteins from two or more different serotypes makes up the viral capsid. The AAV particle also includes chemically modified forms bearing ligands adsorbed to the capsid surface. For example, such ligands may include antibodies for targeting a particular cell surface receptor. NON-VIRAL PARTICLE In some embodiments, the vector is a non-viral particle. In some embodiments, the vector is a non-viral particle, wherein the non-viral particle comprises a peptide, wherein the peptide: (a) comprises or consists of the amino acid sequence PGVPGRF (SEQ ID NO: 21), or a variant thereof having up to two amino acid substitutions, additions or deletions; or (b) comprises or consists of the amino acid sequence NGVRSVG (SEQ ID NO: 23), or i t th f h i t t i id b tit ti dditi d l ti In some embodiments, the vector is a non-viral particle, wherein the non-viral particle comprises a peptide, wherein the peptide: (a) comprises or consists of the amino acid sequence AGPGVPGRF (SEQ ID NO: 22), or a variant thereof having up to two amino acid substitutions, additions or deletions; or (b) comprises or consists of the amino acid sequence AGNGVRSVG (SEQ ID NO: 24), or a variant thereof having up to two amino acid substitutions, additions or deletions. In some embodiments, the non-viral particle is a nanoparticle. In some embodiments, the non- viral particle is a lipid nanoparticle. In some embodiments, the non-viral particle is a liposome. EXEMPLARY VECTORS In some embodiments, the vector comprises from 5’ to 3’: the promoter; the transgene; and the one or more miRNA target sequence. In some embodiments, the vector comprises from 5’ to 3’: the Ef1α promoter; the transgene encoding IL-10; and the one or more miRNA target sequence. In some embodiments, the vector comprises from 5’ to 3’: the Mx1 minimal promoter; the transgene encoding IL-10; and the one or more miRNA target sequence. In some embodiments, the vector comprises from 5’ to 3’: the one or more GAS; the Mx1 minimal promoter; the transgene encoding IL-10; and the one or more miRNA target sequence. Exemplary vectors include: CAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAAT ATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAG TATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACC CAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTG GATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTT TAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTATTGACGCCGGGCAAGAGCAACTCGGTCGCCGCA TACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATG ACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGAC AACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTG ATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGTAGCA AGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTA TTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGT AAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACA GATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATATATAC TTTAGATTGATTTAAAACTTCATTTTTAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTC ATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGG ATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAG CGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACTGGCTTCAGCAGAGCG CAGATACCAAATACTGTCCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACC GCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTA CCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGC ACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAG CGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGC GCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGA CTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGC CTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGTTCTTTCCTGCGTTATCCCCTGATT CTGTGGATAACCGTATTACCGCCTTTGAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGC AGCGAGTCAGTGAGCGAGGAAGCGGAAGAGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTTGGCC GATTCATTAATGCAGCTGGCACGACAGGTTTCCCGACTGGAAAGCGGGCAGTGAGCGCAACGCAATTA ATGTGAGTTAGCTCACTCATTAGGCACCCCAGGCTTTACACTTTATGCTTCCGGCTCGTATGTTGTGT GGAATTGTGAGCGGATAACAATTTCACACAGGAAACAGCTATGACCATGATTACGCCAAGCGCGCAAT TAACCCTCACTAAAGGGAACAAAAGCTGGAGCTGCAAGCTTGGCCATTGCATACGTTGTATCCATATC ATAATATGTACATTTATATTGGCTCATGTCCAACATTACCGCCATGTTGACATTGATTATTGACTAGT TATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATAACT TACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGACGTATG TTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCC CACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATG GCCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTAT TAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGAC TCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGTTTTGGCACCAAAATCAACG GGACTTTCCAAAATGTCGTAACAACTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGTGGG AGGTCTATATAAGCAGAGCTCGTTTAGTGAACCGGGGTCTCTCTGGTTAGACCAGATCTGAGCCTGGG AGCTCTCTGGCTAACTAGGGAACCCACTGCTTAAGCCTCAATAAAGCTTGCCTTGAGTGCTTCAAGTA GTGTGTGCCCGTCTGTTGTGTGACTCTGGTAACTAGAGATCCCTCAGACCCTTTTAGTCAGTGTGGAA AATCTCTAGCAGTGGCGCCCGAACAGGGACCTGAAAGCGAAAGGGAAACCAGAGCTCTCTCGACGCAG GACTCGGCTTGCTGAAGCGCGCACGGCAAGAGGCGAGGGGCGGCGACTGGTGAGTACGCCAAAAATTT TGACTAGCGGAGGCTAGAAGGAGAGAGATGGGTGCGAGAGCGTCAGTATTAAGCGGGGGAGAATTAGA TCGCGATGGGAAAAAATTCGGTTAAGGCCAGGGGGAAAGAAAAAATATAAATTAAAACATATAGTATG GGCAAGCAGGGAGCTAGAACGATTCGCAGTTAATCCTGGCCTGTTAGAAACATCAGAAGGCTGTAGAC AAATACTGGGACAGCTACAACCATCCCTTCAGACAGGATCAGAAGAACTTAGATCATTATATAATACA GTAGCAACCCTCTATTGTGTGCATCAAAGGATAGAGATAAAAGACACCAAGGAAGCTTTAGACAAGAT AGAGGAAGAGCAAAACAAAAGTAAGACCACCGCACAGCAAGCGGCCGCTGATCTTCAGACCTGGAGGA GGAGATATGAGGGACAATTGGAGAAGTGAATTATATAAATATAAAGTAGTAAAAATTGAACCATTAGG AGTAGCACCCACCAAGGCAAAGAGAAGAGTGGTGCAGAGAGAAAAAAGAGCAGTGGGAATAGGAGCTT TGTTCCTTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGCGCAGCCTCAATGACGCTGACGGTACAG GCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAATTTGCTGAGGGCTATTGAGGCGCAACA GCATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAGCTCCAGGCAAGAATCCTGGCTGTGGAAAGAT ACCTAAAGGATCAACAGCTCCTGGGGATTTGGGGTTGCTCTGGAAAACTCATTTGCACCACTGCTGTG CCTTGGAATGCTAGTTGGAGTAATAAATCTCTGGAACAGATTTGGAATCACACGACCTGGATGGAGTG GGACAGAGAAATTAACAATTACACAAGCTTAATACACTCCTTAATTGAAGAATCGCAAAACCAGCAAG AAAAGAATGAACAAGAATTATTGGAATTAGATAAATGGGCAAGTTTGTGGAATTGGTTTAACATAACA AATTGGCTGTGGTATATAAAATTATTCATAATGATAGTAGGAGGCTTGGTAGGTTTAAGAATAGTTTT TGCTGTACTTTCTATAGTGAATAGAGTTAGGCAGGGATATTCACCATTATCGTTTCAGACCCACCTCC CAACCCCGAGGGGACCCGACAGGCCCGAAGGAATAGAAGAAGAAGGTGGAGAGAGAGACAGAGACAGA TCCATTCGATTAGTGAACGGATCTCGACGGTATCGGTTAACTTTTAAAAGAAAAGGGGGGATTGGGGG GTACAGTGCAGGGGAAAGAATAGTAGACATAATAGCAACAGACATACAAACTAAAGAATTACAAAAAC AAATTACAAAAATTCAAAATTTTATCGATAAGCTTTGCAAAGATGGATAAAGTTTTAAACAGAGAGGA ATCTTTGCAGCTAATGGACCTTCTAGGTCTTGAAAGGAGTGGGAATTGGCTCCGGTGCCCGTCAGTGG GCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGGGGGAGGGGTCGGCAATTGAACCGGTGCCTA GAGAAGGTGGCGCGGGGTAAACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTG GGGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCAACGGGTTTGCCGCCAGA ACACAGGTAAGTGCCGTGTGTGGTTCCCGCGGGCCTGGCCTCTTTACGGGTTATGGCCCTTGCGTGCC TTGAATTACTTCCACTGGCTGCAGTACGTGATTCTTGATCCCGAGCTTCGGGTTGGAAGTGGGTGGGA GAGTTCGAGGCCTTGCGCTTAAGGAGCCCCTTCGCCTCGTGCTTGAGTTGAGGCCTGGCCTGGGCGCT GGGGCCGCCGCGTGCGAATCTGGTGGCACCTTCGCGCCTGTCTCGCTGCTTTCGATAAGTCTCTAGCC ATTTAAAATTTTTGATGACCTGCTGCGACGCTTTTTTTCTGGCAAGATAGTCTTGTAAATGCGGGCCA AGATCTGCACACTGGTATTTCGGTTTTTGGGGCCGCGGGCGGCGACGGGGCCCGTGCGTCCCAGCGCA CATGTTCGGCGAGGCGGGGCCTGCGAGCGCGGCCACCGAGAATCGGACGGGGGTAGTCTCAAGCTGGC CGGCCTGCTCTGGTGCCTGGCCTCGCGCCGCCGTGTATCGCCCCGCCCTGGGCGGCAAGGCTGGCCCG GTCGGCACCAGTTGCGTGAGCGGAAAGATGGCCGCTTCCCGGCCCTGCTGCAGGGAGCTCAAAATGGA GGACGCGGCGCTCGGGAGAGCGGGCGGGTGAGTCACCCACACAAAGGAAAAGGGCCTTTCCGTCCTCA GCCGTCGCTTCATGTGACTCCACGGAGTACCGGGCGCCGTCCAGGCACCTCGATTAGTTCTCGAGCTT TTGGAGTACGTCGTCTTTAGGTTGGGGGGAGGGGTTTTATGCGATGGAGTTTCCCCACACTGAGTGGG TGGAGACTGAAGTTAGGCCAGCTTGGCACTTGATGTAATTCTCCTTGGAATTTGCCCTTTTTGAGTTT GGATCTTGGTTCATTCTCAAGCCTCAGACAGTGGTTCAAAGTTTTTTTCTTCCATTTCAGGTGTCGTG AGGAATTCTGCAGTCGATCGACGGTACCGCGGGCCCGGGATCCCCACCATGCACAGCTCAGCACTGCT CTGTTGCCTGGTCCTCCTGACTGGGGTGAGGGCCAGCCCAGGCCAGGGCACCCAGTCTGAGAACAGCT GCACCCACTTCCCAGGCAACCTGCCTAACATGCTTCGAGATCTCCGAGATGCCTTCAGCAGAGTGAAG ACTTTCTTTCAAATGAAGGATCAGCTGGACAACTTGTTGTTAAAGGAGTCCTTGCTGGAGGACTTTAA GGGTTACCTGGGTTGCCAAGCCTTGTCTGAGATGATCCAGTTTTACCTGGAGGAGGTGATGCCCCAAG CTGAGAACCAAGACCCAGACATCAAGGCGCATGTGAACTCCCTGGGGGAGAACCTGAAGACCCTCAGG CTGAGGCTACGGCGCTGTCATCGATTTCTTCCCTGTGAAAACAAGAGCAAGGCCGTGGAGCAGGTGAA GAATGCCTTTAATAAGCTCCAAGAGAAAGGCATCTACAAAGCCATGAGTGAGTTTGACATCTTCATCA ACTACATAGAAGCCTACATGACAATGAAGATACGAAACTGAGTCGACAATCAACCTCTGGATTACAAA ATTTGTGAAAGATTGACTGGTATTCTTAACTATGTTGCTCCTTTTACGCTATGTGGATACGCTGCTTT AATGCCTTTGTATCATGCTATTGCTTCCCGTATGGCTTTCATTTTCTCCTCCTTGTATAAATCCTGGT TGCTGTCTCTTTATGAGGAGTTGTGGCCCGTTGTCAGGCAACGTGGCGTGGTGTGCACTGTGTTTGCT GACGCAACCCCCACTGGTTGGGGCATTGCCACCACCTGTCAGCTCCTTTCCGGGACTTTCGCTTTCCC CCTCCCTATTGCCACGGCGGAACTCATCGCCGCCTGCCTTGCCCGCTGCTGGACAGGGGCTCGGCTGT TGGGCACTGACAATTCCGTGGTGTTGTCGGGGAAGCTGACGTCCTTTCCATGGCTGCTCGCCTGTGTT GCCACCTGGATTCTGCGCGGGACGTCCTTCTGCTACGTCCCTTCGGCCCTCAATCCAGCGGACCTTCC TTCCCGCGGCCTGCTGCCGGCTCTGCGGCCTCTTCCGCGTCTTCGCCTTCGCCCTCAGACGAGTCGGA TCTCCCTTTGGGCCGCCTCCCCGCCTGGAATGATATCCTCGAGCCCGGGCGATATATTGCCTTATTTC CGATTATTGCCTTATTTCGCATTATTGCCTTATTTCTCACTATTGCCTTATTTCCGATCCCGGGGTTT AAACCGATCAACAAAATCACTGATGCTGGACGATCAACAAAATCACTGATGCTGGACGATCAACAAAA TCACTGATGCTGGATCACCAACAAAATCACTGATGCTGGACGATGTTTAAACCCTGCAGGCGATCAGC TATGCCAGCATCTTGCCCGATCAGCTATGCCAGCATCTTGCCCGATCAGCTATGCCAGCATCTTGCCT CACCAGCTATGCCAGCATCTTGCCCGATCCTGCAGGAGATCTTCGAGCTCGGTACCTTTAAGACCAAT GACTTACAAGGCAGCTGTAGATCTTAGCCACTTTTTAAAAGAAAAGGGGGGACTGGAAGGGCTAATTC ACTCCCAACGAAGACAAGATCTGCTTTTTGCTTGTACTGGGTCTCTCTGGTTAGACCAGATCTGAGCC TGGGAGCTCTCTGGCTAACTAGGGAACCCACTGCTTAAGCCTCAATAAAGCTTGCCTTGAGTGCTTCA AGTAGTGTGTGCCCGTCTGTTGTGTGACTCTGGTAACTAGAGATCCCTCAGACCCTTTTAGTCAGTGT GGAAAATCTCTAGCAGTAGTAGTTCATGTCATCTTATTATTCAGTATTTATAACTTGCAAAGAAATGA ATATCAGAGAGTGAGAGGAACTTGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCATCAC AAATTTCACAAATAAAGCATTTTTTTCACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAATGTAT CTTATCATGTCTGGCTCTAGCTATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATG GCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTATTCCAGAAGTAG TGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCGTCGAGACGTACCCAATTCGCCCTATAGTGAGTCG TATTACGCGCGCTCACTGGCCGTCGTTTTACAACGTCGTGACTGGGAAAACCCTGGCGTTACCCAACT TAATCGCCTTGCAGCACATCCCCCTTTCGCCAGCTGGCGTAATAGCGAAGAGGCCCGCACCGATCGCC CTTCCCAACAGTTGCGCAGCCTGAATGGCGAATGGCGCGACGCGCCCTGTAGCGGCGCATTAAGCGCG GCGGGTGTGGTGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTCGC TTTCTTCCCTTCCTTTCTCGCCACGTTCGCCGGCTTTCCCCGTCAAGCTCTAAATCGGGGGCTCCCTT TAGGGTTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAAACTTGATTAGGGTGATGGTTCACGT AGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTTGGAGTCCACGTTCTTTAATAGTGG ACTCTTGTTCCAAACTGGAACAACACTCAACCCTATCTCGGTCTATTCTTTTGATTTATAAGGGATTT TGCCGATTTCGGCCTATTGGTTAAAAAATGAGCTGATTTAACAAAAATTTAACGCGAATTTTAACAAA ATATTAACGTTTACAATTTCC (SEQ ID NO: 10 – Constitutive IL-10 construct) Ef1α promoter - Bold Il-10 - Underlined miR-124 target sequence - Double underlined miR-338 target sequence - Dashed underlined miR-31 target sequence - Dotted underlined CAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAAT ATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAG TATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACC CAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTG GATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTT TAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTATTGACGCCGGGCAAGAGCAACTCGGTCGCCGCA TACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATG ACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGAC AACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTG ATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGTAGCA ATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAAT AGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTA TTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGT AAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACA GATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATATATAC TTTAGATTGATTTAAAACTTCATTTTTAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTC ATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGG ATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAG CGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACTGGCTTCAGCAGAGCG CAGATACCAAATACTGTCCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACC GCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTA ACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAG CGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGC GCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGA CTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGC CTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGTTCTTTCCTGCGTTATCCCCTGATT CTGTGGATAACCGTATTACCGCCTTTGAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGC AGCGAGTCAGTGAGCGAGGAAGCGGAAGAGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTTGGCC GATTCATTAATGCAGCTGGCACGACAGGTTTCCCGACTGGAAAGCGGGCAGTGAGCGCAACGCAATTA ATGTGAGTTAGCTCACTCATTAGGCACCCCAGGCTTTACACTTTATGCTTCCGGCTCGTATGTTGTGT GGAATTGTGAGCGGATAACAATTTCACACAGGAAACAGCTATGACCATGATTACGCCAAGCGCGCAAT TAACCCTCACTAAAGGGAACAAAAGCTGGAGCTGCAAGCTTGGCCATTGCATACGTTGTATCCATATC ATAATATGTACATTTATATTGGCTCATGTCCAACATTACCGCCATGTTGACATTGATTATTGACTAGT TATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATAACT TACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGACGTATG TTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCC CACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATG GCCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTAT TAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGAC TCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGTTTTGGCACCAAAATCAACG GGACTTTCCAAAATGTCGTAACAACTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGTGGG AGGTCTATATAAGCAGAGCTCGTTTAGTGAACCGGGGTCTCTCTGGTTAGACCAGATCTGAGCCTGGG AGCTCTCTGGCTAACTAGGGAACCCACTGCTTAAGCCTCAATAAAGCTTGCCTTGAGTGCTTCAAGTA GTGTGTGCCCGTCTGTTGTGTGACTCTGGTAACTAGAGATCCCTCAGACCCTTTTAGTCAGTGTGGAA AATCTCTAGCAGTGGCGCCCGAACAGGGACCTGAAAGCGAAAGGGAAACCAGAGCTCTCTCGACGCAG GACTCGGCTTGCTGAAGCGCGCACGGCAAGAGGCGAGGGGCGGCGACTGGTGAGTACGCCAAAAATTT TGACTAGCGGAGGCTAGAAGGAGAGAGATGGGTGCGAGAGCGTCAGTATTAAGCGGGGGAGAATTAGA TCGCGATGGGAAAAAATTCGGTTAAGGCCAGGGGGAAAGAAAAAATATAAATTAAAACATATAGTATG GGCAAGCAGGGAGCTAGAACGATTCGCAGTTAATCCTGGCCTGTTAGAAACATCAGAAGGCTGTAGAC AAATACTGGGACAGCTACAACCATCCCTTCAGACAGGATCAGAAGAACTTAGATCATTATATAATACA GTAGCAACCCTCTATTGTGTGCATCAAAGGATAGAGATAAAAGACACCAAGGAAGCTTTAGACAAGAT AGAGGAAGAGCAAAACAAAAGTAAGACCACCGCACAGCAAGCGGCCGCTGATCTTCAGACCTGGAGGA GGAGATATGAGGGACAATTGGAGAAGTGAATTATATAAATATAAAGTAGTAAAAATTGAACCATTAGG AGTAGCACCCACCAAGGCAAAGAGAAGAGTGGTGCAGAGAGAAAAAAGAGCAGTGGGAATAGGAGCTT TGTTCCTTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGCGCAGCCTCAATGACGCTGACGGTACAG GCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAATTTGCTGAGGGCTATTGAGGCGCAACA GCATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAGCTCCAGGCAAGAATCCTGGCTGTGGAAAGAT ACCTAAAGGATCAACAGCTCCTGGGGATTTGGGGTTGCTCTGGAAAACTCATTTGCACCACTGCTGTG CCTTGGAATGCTAGTTGGAGTAATAAATCTCTGGAACAGATTTGGAATCACACGACCTGGATGGAGTG GGACAGAGAAATTAACAATTACACAAGCTTAATACACTCCTTAATTGAAGAATCGCAAAACCAGCAAG AAAAGAATGAACAAGAATTATTGGAATTAGATAAATGGGCAAGTTTGTGGAATTGGTTTAACATAACA AATTGGCTGTGGTATATAAAATTATTCATAATGATAGTAGGAGGCTTGGTAGGTTTAAGAATAGTTTT TGCTGTACTTTCTATAGTGAATAGAGTTAGGCAGGGATATTCACCATTATCGTTTCAGACCCACCTCC CAACCCCGAGGGGACCCGACAGGCCCGAAGGAATAGAAGAAGAAGGTGGAGAGAGAGACAGAGACAGA TCCATTCGATTAGTGAACGGATCTCGACGGTATCGGTTAACTTTTAAAAGAAAAGGGGGGATTGGGGG GTACAGTGCAGGGGAAAGAATAGTAGACATAATAGCAACAGACATACAAACTAAAGAATTACAAAAAC AAATTACAAAAATTCAAAATTTTATGGCGCGCCTTCCCGGAATTCCCGGAATTCCCGGAATTCCCGGA AGCATGCGAGCTGGGGGATGTTCTCTGCAGAGCAGGGCTCTCCTCTGGAGAGAAGGGCAAGGTGCAGC AGGCCCCAGAAGGCCAGCACTTCTCACCCCCACCAGCCCTGCAGTAGCAGTGTGCTCAGACCTCTAAA CCTGTAGTCACAAGGGACCCAGAAGGGCTGGCAGGGCTCCTCAGTGATTCTGGTATGGTTTGTCTCTG ACCCTTCCTAGTGTAGCTGGAAGAATCCAGTGAAAAGAGAAAGTTAGTCTAGGTTGTGTTCAACTGAG AGGAGGTCAGGCTGAAGGCTCAGCACAGAGCTGGAAGGGTCCTGGGAAAGCAGGCAGCCATCTGAACT GGTGTCCATACTGCATGTGTCTTGGTGGGCTGAGCCTACAATATCGATTTCCCAACCTCAGTACCAAG CCAAGGCCCCTCAGGGTGAGTTTCGTTTCTGAGCTCCTTTCATATGTGGTGGGGGTGTGGGCACAGCA AGCTCAGGCTTTTTCACGGTTTCAATTCTCCTCTGGAAGGGGTGGAGCCAGCACTATTTAAAGAGGTC TGAGCCCTGGCAGCTGCACACTCTCTGGATCCCCACCATGCACAGCTCAGCACTGCTCTGTTGCCTGG TCCTCCTGACTGGGGTGAGGGCCAGCCCAGGCCAGGGCACCCAGTCTGAGAACAGCTGCACCCACTTC CCAGGCAACCTGCCTAACATGCTTCGAGATCTCCGAGATGCCTTCAGCAGAGTGAAGACTTTCTTTCA AATGAAGGATCAGCTGGACAACTTGTTGTTAAAGGAGTCCTTGCTGGAGGACTTTAAGGGTTACCTGG GTTGCCAAGCCTTGTCTGAGATGATCCAGTTTTACCTGGAGGAGGTGATGCCCCAAGCTGAGAACCAA GACCCAGACATCAAGGCGCATGTGAACTCCCTGGGGGAGAACCTGAAGACCCTCAGGCTGAGGCTACG GCGCTGTCATCGATTTCTTCCCTGTGAAAACAAGAGCAAGGCCGTGGAGCAGGTGAAGAATGCCTTTA ATAAGCTCCAAGAGAAAGGCATCTACAAAGCCATGAGTGAGTTTGACATCTTCATCAACTACATAGAA GCCTACATGACAATGAAGATACGAAACTGAGTCGACAATCAACCTCTGGATTACAAAATTTGTGAAAG ATTGACTGGTATTCTTAACTATGTTGCTCCTTTTACGCTATGTGGATACGCTGCTTTAATGCCTTTGT ATCATGCTATTGCTTCCCGTATGGCTTTCATTTTCTCCTCCTTGTATAAATCCTGGTTGCTGTCTCTT TATGAGGAGTTGTGGCCCGTTGTCAGGCAACGTGGCGTGGTGTGCACTGTGTTTGCTGACGCAACCCC CACTGGTTGGGGCATTGCCACCACCTGTCAGCTCCTTTCCGGGACTTTCGCTTTCCCCCTCCCTATTG CCACGGCGGAACTCATCGCCGCCTGCCTTGCCCGCTGCTGGACAGGGGCTCGGCTGTTGGGCACTGAC AATTCCGTGGTGTTGTCGGGGAAGCTGACGTCCTTTCCATGGCTGCTCGCCTGTGTTGCCACCTGGAT TCTGCGCGGGACGTCCTTCTGCTACGTCCCTTCGGCCCTCAATCCAGCGGACCTTCCTTCCCGCGGCC TGCTGCCGGCTCTGCGGCCTCTTCCGCGTCTTCGCCTTCGCCCTCAGACGAGTCGGATCTCCCTTTGG GCCGCCTCCCCGCCTGGAATGATATCCTCGAGCCCGGGCGATATATTGCCTTATTTCCGATTATTGCC TTATTTCGCATTATTGCCTTATTTCTCACTATTGCCTTATTTCCGATCCCGGGGTTTAAACCGATCAA CAAAATCACTGATGCTGGACGATCAACAAAATCACTGATGCTGGACGATCAACAAAATCACTGATGCT GGATCACCAACAAAATCACTGATGCTGGACGATGTTTAAACCCTGCAGGCGATCAGCTATGCCAGCAT CTTGCCCGATCAGCTATGCCAGCATCTTGCCCGATCAGCTATGCCAGCATCTTGCCTCACCAGCTATG CCAGCATCTTGCCCGATCCTGCAGGAGATCTTCGAGCTCGGTACCTTTAAGACCAATGACTTACAAGG CAGCTGTAGATCTTAGCCACTTTTTAAAAGAAAAGGGGGGACTGGAAGGGCTAATTCACTCCCAACGA AGACAAGATCTGCTTTTTGCTTGTACTGGGTCTCTCTGGTTAGACCAGATCTGAGCCTGGGAGCTCTC TGGCTAACTAGGGAACCCACTGCTTAAGCCTCAATAAAGCTTGCCTTGAGTGCTTCAAGTAGTGTGTG CCCGTCTGTTGTGTGACTCTGGTAACTAGAGATCCCTCAGACCCTTTTAGTCAGTGTGGAAAATCTCT AGCAGTAGTAGTTCATGTCATCTTATTATTCAGTATTTATAACTTGCAAAGAAATGAATATCAGAGAG TGAGAGGAACTTGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCATCACAAATTTCACAA ATAAAGCATTTTTTTCACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAATGTATCTTATCATGTC TGGCTCTAGCTATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGACTAATT TTTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTT TTTTGGAGGCCTAGGCTTTTGCGTCGAGACGTACCCAATTCGCCCTATAGTGAGTCGTATTACGCGCG CTCACTGGCCGTCGTTTTACAACGTCGTGACTGGGAAAACCCTGGCGTTACCCAACTTAATCGCCTTG CAGCACATCCCCCTTTCGCCAGCTGGCGTAATAGCGAAGAGGCCCGCACCGATCGCCCTTCCCAACAG TTGCGCAGCCTGAATGGCGAATGGCGCGACGCGCCCTGTAGCGGCGCATTAAGCGCGGCGGGTGTGGT GGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTCGCTTTCTTCCCTT CCTTTCTCGCCACGTTCGCCGGCTTTCCCCGTCAAGCTCTAAATCGGGGGCTCCCTTTAGGGTTCCGA TTTAGTGCTTTACGGCACCTCGACCCCAAAAAACTTGATTAGGGTGATGGTTCACGTAGTGGGCCATC GCCCTGATAGACGGTTTTTCGCCCTTTGACGTTGGAGTCCACGTTCTTTAATAGTGGACTCTTGTTCC AAACTGGAACAACACTCAACCCTATCTCGGTCTATTCTTTTGATTTATAAGGGATTTTGCCGATTTCG GCCTATTGGTTAAAAAATGAGCTGATTTAACAAAAATTTAACGCGAATTTTAACAAAATATTAACGTT TACAATTTCC (SEQ ID NO: 11 – Inducible IL-10 construct) Gamma interferon activation site (4x repeats) - bold Mx1 minimal promoter - Italics Il-10 - Underlined miR-124 target sequence - Double underlined miR-338 target sequence - Dashed underlined miR-31 target sequence - Dotted underlined In some embodiments, the vector comprises or consists of a nucleotide sequence that has at least 70% sequence identity to SEQ ID NO: 10 or a fragment thereof. Suitably, the vector comprises or consists of a nucleotide sequence that has at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 10 or a fragment thereof. In some embodiments, the vector comprises or consists of the nucleotide sequence SEQ ID NO: 10 or a fragment thereof. In some embodiments, the vector comprises or consists of a nucleotide sequence that has at least 70% sequence identity to SEQ ID NO: 11 or a fragment thereof. Suitably, the vector comprises or consists of a nucleotide sequence that has at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 11 or a fragment thereof. In some embodiments, the vector comprises or consists of the nucleotide sequence SEQ ID NO: 11 or a fragment thereof. A further exemplary vector is: TTGGCCACTCCCTCTCTGCGCGCTCGCTCGCTCACTGAGGCCGCCCGGGCAAAGCCCGGGCGGCCTCA GTGAGCGAGCGAGCGCGCAGAGAGGGAGTGGCCAACTCCATCACTAGGGGTTCCTACTAGTAACATAT CCTGGTGTGGAGTAGGGGACGCTGCTCTGACAGAGGCTCGGGGGCCTGAGCTGGCTCTGTGAGCTGGG GAGGAGGCAGACAGCCAGGCCTTGTCTGCAAGCAGACCTGGCAGCATTGGGCTGGCCGCCCCCCAGGG CCTCCTCTTCATGCCCAGTGAATGACTCACCTTGGCACAGACACAATGTTCGGGGTGGGCACAGTGCC TGCTTCCCGCCGCACCCCAGCCCCCCTCAAATGCCTTCCGAGAAGCCCATTGAGCAGGGGGCTTGCAT TGCACCCCAGCCTGACAGCCTGGCATCTTGGGATAAAAGCAGCACAGCCCCCTAGGGGCTGCCCTTGC TGTGTGGCGCCACCGGCGGTGGAGAACAAGGCTCTATTCAGCCTGTGCCCAGGAAAGGGGATCAGGGG ATGCCCAGGCATGGACAGTGGGTGGCAGGGGGGGAGAGGAGGGCTGTCTGCTTCCCAGAAGTCCAAGG ACACAAATGGGTGAGGGGAGAGCTCTCCCCATAGCTGGGCTGCGGCCCAACCCCACCCCCTCAGGCTA TGCCAGGGGGTGTTGCCAGGGGCACCCGGGCATCGCCAGTCTAGCCCACTCCTTCATAAAGCCCTCGT ATCCCAGGAGCGAGCAGAGCCAGAGCAGGTTGGAGAGGAGACGCATCACCTCTGCTGCTTGCCTAAAT GCACAGCTCAGCACTGCTCTGTTGCCTGGTCCTCCTGACTGGGGTGAGGGCCAGCCCAGGCCAGGGCA CCCAGTCTGAGAACAGCTGCACCCACTTCCCAGGCAACCTGCCTAACATGCTTCGAGATCTCCGAGAT GCCTTCAGCAGAGTGAAGACTTTCTTTCAAATGAAGGATCAGCTGGACAACTTGTTGTTAAAGGAGTC CTTGCTGGAGGACTTTAAGGGTTACCTGGGTTGCCAAGCCTTGTCTGAGATGATCCAGTTTTACCTGG AGGAGGTGATGCCCCAAGCTGAGAACCAAGACCCAGACATCAAGGCGCATGTGAACTCCCTGGGGGAG AACCTGAAGACCCTCAGGCTGAGGCTACGGCGCTGTCATCGATTTCTTCCCTGTGAAAACAAGAGCAA GGCCGTGGAGCAGGTGAAGAATGCCTTTAATAAGCTCCAAGAGAAAGGCATCTACAAAGCCATGAGTG AGTTTGACATCTTCATCAACTACATAGAAGCCTACATGACAATGAAGATACGAAACTAAGATCCTAAT CAACCTCTGGATTACAAAATTTGTGAAAGATTGACTGGTATTCTTAACTATGTTGCTCCTTTTACGCT CCTTGTATAAATCCTGGTTGCTGTCTCTTTATGAGGAGTTGTGGCCCGTTGTCAGGCAACGTGGCGTG GTGTGCACTGTGTTTGCTGACGCAACCCCCACTGGTTGGGGCATTGCCACCACCTGTCAGCTCCTTTC CGGGACTTTCGCTTTCCCCCTCCCTATTGCCACGGCGGAACTCATCGCCGCCTGCCTTGCCCGCTGCT GGACAGGGGCTCGGCTGTTGGGCACTGACAATTCCGTGGTGTTGTCGGGGAAATCATCGTCCTTTCCT TGGCTGCTCGCCTGTGTTGCCACCTGGATTCTGCGCGGGACGTCCTTCTGCTACGTCCCTTCGGCCCT CAATCCAGCGGACCTTCCTTCCCGCGGCCTGCTGCCGGCTCTGCGGCCTCTTCCGCGTCTTCGCCTTC GCCCTCAGACGAGTCGGATCTCCCTTTGGGCCGCCTCCCCGCCTGAATTCTGCATACTTCTTTACATT CCAGATATCTGCATCAAACACCATTGTCACACTCCATCGCGATCACGCGAGCCGAACGAACAAACCCA ACAACATGAAACTACCTAGCGCTTCTATTCAGCATGATGTCTTTCGTATACACAAATTCGGTTCTACA GGGTAACCTAGGCTGCATGTTTAAACATACATACTTCTTTACATTCCAGATATCTGCATCAAACACCA TTGTCACACTCCATCGCGATCACGCGAGCCGAACGAACAAACCCAACAACATGAAACTACCTAGCGCT TCTATTCAGCATGATGTCTTTCGTATACACAAATTCGGTTCTACAGGGTAACCTAGGCTGCATGTTTA AACATACATACTTCTTTACATTCCAGATATCTGCATCAAACACCATTGTCACACTCCATCGCGATCAC GCGAGCCGAACGAACAAACCCAACAACATGAAACTACCTAGCGCTTCTATTCAGCATGATGTCTTTCG TATACACAAATTCGGTTCTACAGGGTAACCTAGGCTGCAGGTACCTTCGAGCAGACATGATAAGATAC ATTGATGAGTTTGGACAAACCACAACTAGAATGCAGTGAAAAAAATGCTTTATTTGTGAAATTTGTGA TGCTATTGCTTTATTTGTAACCATTATAAGCTGCAATAAACAAGTTAACAACAACAATTGCATTCATT TTATGTTTCAGGTTCAGGGGGAGATGTGGGAGGTTTTTTAAAGCAAGTAAAACCTCTACAAATGTGGT AAAATCAAGCTTAGGAACCCCTAGTGATGGAGTTGGCCACTCCCTCTCTGCGCGCTCGCTCGCTCACT GAGGCCGGGCGACCAAAGGTCGCCCGACGCCCGGGCTTTGCCCGGGCGGCCTCAGTGAGCGAGCGAGC GCGCAGAGAGGGAGTGGCCAAGCTAGCGGGCGATTAAGGAAAGGGCTAGATCATTCTTGAAGACGAAA GGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATGATAATAATGGTTTCTTAGACGTCAGGTG GCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTAT CCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCA ACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAA CGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTC AACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGT TCTGCTATGTGGCGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACT ATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTA AGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGAT CGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTT GGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGTAGCAATGGCA ACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTG GATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTG ATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCC TCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGC TGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATATATACTTTAGA TTGATTTAAAACTTCATTTTTAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACC AAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTC TTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGG TTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATA CCAAATACTGTTCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTAC ATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGT TGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAG CCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCAC GCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGA GGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAG CGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTT ACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGTAATAAACACACACACACCAACAACCGTGGT TGGTTGTTGTGTTGGTTTATTCTCGAG (SEQ ID NO: 35) GFAP promoter - Bold Il-10 - Underlined In some embodiments, the vector comprises or consists of a nucleotide sequence that has at least 70% sequence identity to SEQ ID NO: 35 or a fragment thereof. Suitably, the vector comprises or consists of a nucleotide sequence that has at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 35 or a fragment thereof. In some embodiments, the vector comprises or consists of the nucleotide sequence SEQ ID NO: 35 or a fragment thereof. VARIANTS, DERIVATIVES, ANALOGUES, HOMOLOGUES AND FRAGMENTS In addition to the specific proteins and nucleotides mentioned herein, the invention also encompasses variants, derivatives, analogues, homologues and fragments thereof. In the context of the invention, a “variant” of any given sequence is a sequence in which the specific sequence of residues (whether amino acid or nucleic acid residues) has been modified in such a manner that the polypeptide or polynucleotide in question retains at least one of its endogenous functions. A variant sequence can be obtained by addition, deletion, substitution, modification, replacement and / or variation of at least one residue present in the naturally occurring polypeptide or polynucleotide. The term “derivative” as used herein in relation to proteins or polypeptides of the invention includes any substitution of, variation of, modification of, replacement of, deletion of and / or addition of one (or more) amino acid residues from or to the sequence, providing that the resultant protein or polypeptide retains at least one of its endogenous functions. The term “analogue” as used herein in relation to polypeptides or polynucleotides includes any mimetic, that is, a chemical compound that possesses at least one of the endogenous functions of the polypeptides or polynucleotides which it mimics. Typically, amino acid substitutions may be made, for example from 1, 2 or 3, to 10 or 20 substitutions, provided that the modified sequence retains the required activity or ability. Amino acid substitutions may include the use of non-naturally occurring analogues. Proteins used in the invention may also have deletions, insertions or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent protein. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity and / or the amphipathic nature of the residues as long as the endogenous function is retained. For example, negatively charged amino acids include aspartic acid and glutamic acid; positively charged amino acids include lysine and arginine; and amino acids with uncharged polar head groups having similar hydrophilicity values include asparagine, glutamine, serine, threonine and tyrosine. Conservative substitutions may be made, for example according to the table below. Amino acids in the same block in the second column and preferably in the same line in the third column may be substituted for each other: The term “homologue” as used herein means an entity having a certain homology with the wild type amino acid sequence or the wild type nucleotide sequence. The term “homology” can be equated with “identity”. In the present context, a homologous sequence is taken to include an amino acid sequence which may be at least 50%, 55%, 65%, 75%, 85% or 90% identical, preferably at least 95%, 96% or 97% or 98% or 99% identical to the subject sequence. Typically, the homologues will can also be considered in terms of similarity (i.e. amino acid residues having similar chemical properties / functions), in the context of the present invention it is preferred to express homology in terms of sequence identity. In the present context, a homologous sequence is taken to include a nucleotide sequence which may be at least 50%, 55%, 65%, 75%, 85% or 90% identical, preferably at least 95%, 96% or 97% or 98% or 99% identical to the subject sequence. Although homology can also be considered in terms of similarity, in the context of the present invention it is preferred to express homology in terms of sequence identity. Preferably, reference to a sequence which has a percent identity to any one of the SEQ ID NOs detailed herein refers to a sequence which has the stated percent identity over the entire length of the SEQ ID NO referred to. Homology comparisons can be conducted by eye, or more usually, with the aid of readily available sequence comparison programs. These commercially available computer programs can calculate percent homology or identity between two or more sequences. Percent homology may be calculated over contiguous sequences, i.e. one sequence is aligned with the other sequence and each amino acid or nucleotide in one sequence is directly compared with the corresponding amino acid or nucleotide in the other sequence, one residue at a time. This is called an “ungapped” alignment. Typically, such ungapped alignments are performed only over a relatively short number of residues. Although this is a very simple and consistent method, it fails to take into consideration that, for example, in an otherwise identical pair of sequences, one insertion or deletion in the amino acid or nucleotide sequence may cause the following residues or codons to be put out of alignment, thus potentially resulting in a large reduction in percent homology when a global alignment is performed. Consequently, most sequence comparison methods are designed to produce optimal alignments that take into consideration possible insertions and deletions without penalising unduly the overall homology score. This is achieved by inserting “gaps” in the sequence alignment to try to maximise local homology. However, these more complex methods assign “gap penalties” to each gap that occurs in the alignment so that, for the same number of identical amino acids or nucleotides, a sequence alignment with as few gaps as possible, reflecting higher relatedness between the two compared sequences, will achieve a higher score than one with many gaps. “Affine gap costs” are typically used that charge a relatively high cost for the existence of a gap and a smaller penalty for each subsequent residue in the gap This is the most commonly used gap scoring system. High gap penalties will of course produce optimised alignments with fewer gaps. Most alignment programs allow the gap penalties to be modified. However, it is preferred to use the default values when using such software for sequence comparisons. For example when using the GCG Wisconsin Bestfit package the default gap penalty for amino acid sequences is -12 for a gap and -4 for each extension. Calculation of maximum percent homology therefore firstly requires the production of an optimal alignment, taking into consideration gap penalties. A suitable computer program for carrying out such an alignment is the GCG Wisconsin Bestfit package (University of Wisconsin, USA; Devereux et al. (1984) Nucleic Acids Research 12: 387). Examples of other software that can perform sequence comparisons include, but are not limited to, the BLAST package, FASTA (Atschul et al. (1990) J. Mol. Biol.403-410) and the GENEWORKS suite of comparison tools. Both BLAST and FASTA are available for offline and online searching. However, for some applications, it is preferred to use the GCG Bestfit program. Another tool, BLAST 2 Sequences, is also available for comparing protein and nucleotide sequences (FEMS Microbiol. Lett. (1999) 174(2):247-50; FEMS Microbiol. Lett. (1999) 177(1):187-8). Although the final percent homology can be measured in terms of identity, the alignment process itself is typically not based on an all-or-nothing pair comparison. Instead, a scaled similarity score matrix is generally used that assigns scores to each pairwise comparison based on chemical similarity or evolutionary distance. An example of such a matrix commonly used is the BLOSUM62 matrix (the default matrix for the BLAST suite of programs). GCG Wisconsin programs generally use either the public default values or a custom symbol comparison table if supplied (see the user manual for further details). For some applications, it is preferred to use the public default values for the GCG package, or in the case of other software, the default matrix, such as BLOSUM62. Once the software has produced an optimal alignment, it is possible to calculate percent homology, preferably percent sequence identity. The software typically does this as part of the sequence comparison and generates a numerical result. “Fragments” are also variants and the term typically refers to a selected region of the polypeptide or polynucleotide that is of interest either functionally or, for example, in an assay. “Fragment” thus refers to an amino acid or nucleic acid sequence that is a portion of a full- length polypeptide or polynucleotide. Such variants may be prepared using standard recombinant DNA techniques such as site- directed mutagenesis. Where insertions are to be made, synthetic DNA encoding the insertion either side of the insertion site may be made. The flanking regions will contain convenient restriction sites corresponding to sites in the naturally-occurring sequence so that the sequence may be cut with the appropriate enzyme(s) and the synthetic DNA ligated into the cut. The DNA is then expressed in accordance with the invention to make the encoded protein. These methods are only illustrative of the numerous standard techniques known in the art for manipulation of DNA sequences and other known techniques may also be used. Codon optimisation The polynucleotides used in the invention may be codon-optimised. Codon optimisation has previously been described in WO 1999 / 41397 and WO 2001 / 79518. Different cells differ in their usage of particular codons. This codon bias corresponds to a bias in the relative abundance of particular tRNAs in the cell type. By altering the codons in the sequence so that they are tailored to match with the relative abundance of corresponding tRNAs, it is possible to increase expression. By the same token, it is possible to decrease expression by deliberately choosing codons for which the corresponding tRNAs are known to be rare in the particular cell type. Thus, an additional degree of translational control is available. Codon usage tables are known in the art for mammalian cells, as well as for a variety of other organisms. METHOD OF TREATMENT In one aspect, the invention provides a method of treatment comprising administering the vector, cell or pharmaceutical composition of the invention to a subject in need thereof. The invention provides a method for treating dopaminergic neurons by administering the vector of the invention. These neurons are vital to diverse brain functions, including: voluntary movement, reward, addiction and stress. Progressive loss of dopaminergic neurons is responsible for neurodegenerative diseases, such as Parkinson’s Disease. In one aspect, the invention provides a method of treating or preventing Parkinson’s disease comprising administering the vector, cell or pharmaceutical composition of the invention to a subject in need thereof. The treatment of mammals, particularly humans, is preferred. Both human and veterinary treatments are within the scope of the invention. In some embodiments, the method of treatment provides the transgene to the central nervous system (CNS) of the subject. In some embodiments, the method of treatment provides the transgene to the microglia of the subject. In some embodiments, the method of treatment provides an improvement in learning and / or cognitive function in the subject. Methods for measuring learning and / or cognitive function are known to the skilled person. For example, in humans the General Practitioner Assessment of Cognition (GPCOG) test may be used. Alternative cognitive tests include but are not limited to the Mini Mental State Examination (MMSE), The Six-item Cognitive Impairment Test (6CIT), Abbreviated Mental Test (AMT) and Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE). PHARMACEUTICAL COMPOSITIONS AND INJECTED SOLUTIONS Although the agents for use in the invention can be administered alone, they will generally be administered in admixture with a pharmaceutical carrier, excipient or diluent, particularly for human therapy. A “pharmaceutical composition” may refer to a preparation which is stable and in a form which is acceptable to the patient. The medicaments, for example vectors and vector particles, of the invention may be formulated into pharmaceutical compositions. These compositions may comprise, in addition to the medicament, a pharmaceutically acceptable carrier, diluent, excipient, buffer, stabiliser or other materials well known in the art. Such materials should be non-toxic and should not interfere with the efficacy of the active ingredient. The precise nature of the carrier or other material may be determined by the skilled person according to the route of administration, e.g. intravenous or intra-arterial. The pharmaceutical composition is typically in liquid form. Liquid pharmaceutical compositions generally include a liquid carrier such as water, petroleum, animal or vegetable oils, mineral oil or synthetic oil. Physiological saline solution, magnesium chloride, dextrose or other saccharide solution, or glycols such as ethylene glycol, propylene glycol or polyethylene glycol may be included. In some cases, a surfactant, such as pluronic acid (PF68) 0.001% may be used. In some cases, serum albumin may be used in the composition. For injection, the active ingredient may be in the form of an aqueous solution which is pyrogen- free, and has suitable pH, isotonicity and stability. The skilled person is well able to prepare suitable solutions using, for example, isotonic vehicles such as Sodium Chloride Injection, Ringer's Injection or Lactated Ringer's Injection. Preservatives, stabilisers, buffers, For delayed release, the medicament may be included in a pharmaceutical composition which is formulated for slow release, such as in microcapsules formed from biocompatible polymers or in liposomal carrier systems according to methods known in the art. Handling of the cell therapy products is preferably performed in compliance with FACT-JACIE International Standards for cellular therapy. The invention further includes the kits comprising the vector, cells and / or pharmaceutical composition of the present invention. Preferably, said kits are for use in the methods and used as described herein, e.g., the therapeutic methods as described herein. Preferably said kits comprise instructions for use of the kit components. ADMINISTRATION In some embodiments, the vector, cell or pharmaceutical composition is administered to a subject systemically or locally. The term “systemic delivery” or “systemic administration” as used herein, means that the agent of the invention is administered into the circulatory system, e.g. to achieve broad distribution of the agent. In contrast, topical or local administration restricts the delivery of the agent to a localised area, e.g. intracerebral administration entails direct injection into the brain. In some embodiments, the vector, cell or pharmaceutical composition is administered intravenously. In some embodiments, the vector, cell or pharmaceutical composition is administered intra- arterially. In some embodiments, the vector, cell or pharmaceutical composition is administered to a subject intracranially or intraparenchymally. In some embodiments, the vector, cell or pharmaceutical composition is administered to a subject intracerebrally. DOSAGE The skilled person can readily determine an appropriate dose of an agent of the invention to administer to a subject without undue experimentation. Typically, a physician will determine the actual dosage which will be most suitable for an individual patient and it will depend on a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound the age body weight general health sex diet mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the individual undergoing therapy. There can of course be individual instances where higher or lower dosage ranges are merited, and such are within the scope of the invention. SUBJECT The term “subject” as used herein refers to either a human or non-human animal. Examples of non-human animals include vertebrates, for example mammals, such as non- human primates (particularly higher primates), dogs, rodents (e.g. mice, rats or guinea pigs), pigs and cats. The non-human animal may be a companion animal. Preferably, the subject is a human. DISEASES Neurodegenerative diseases are diseases which primarily affect neurons. These diseases result in the progressive loss of structure or function of nerve cells (neurons) including neuronal cell death. This causes problems with movement (called ataxias), or mental functioning (called dementias). The vector, cell or pharmaceutical composition of the invention may be administered to a subject in a method for treating and / or delaying progression of a neurodegenerative disease. The subject may have a neurodegenerative disease, i.e. has been diagnosed as having the neurodegenerative disease or is suspected as having the neurodegenerative disease, or may be asymptomatic. The subject may have a genetic predisposition to the neurodegenerative disease. The subject may have one or more family members with a neurodegenerative disease. In some embodiments, the neurodegenerative disease is Parkinson’s disease. In some embodiments, the neurodegenerative disease is a Parkinson’s disease-related disorder. Preferably, the Parkinson’s disease-related disorder is Parkinson’s dementia. Preferably, the Parkinson’s disease-related disorder is dementia with Lewy bodies. In some embodiments, the neurodegenerative disease is lower body Parkinson’s syndrome. In some embodiments, the neurodegenerative disease is Alzheimer’s disease, frontotemporal dementia, Pick disease, Multiple systemic atrophy (MSA) or multiple sclerosis. In some embodiments, the neurodegenerative disorder is associated with Lewy bodies. Lewy bodies are abnormal aggregates of protein that develop inside nerve cells and may be found within the substantia nigra or within the cortex. Lewy bodies comprise alpha-synuclein associated with other proteins which may include ubiquitin, neurofilament protein and alpha B crystallin. Lewy neurites may be associated with Lewy bodies. In some embodiments, the neurodegenerative disease is dementia with Lewy bodies. In some embodiments, alpha-synuclein aggregates are decreased, for example in the substantia nigra pars compacta (SNpc). The decrease may be, for example, by at least about 50%, at least about 60%, at least about 70%, at least about 80% or at least about 90%. Amounts of alpha-synuclein aggregates may be determined using methods known in the art, for example as described herein. In some embodiments, microglial phagocytic capacity is increased. The increase may be, for example, by at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5- fold, at least about 6-fold, at least about 7-fold, at least about 8-fold, at least about 9-fold or at least about 10-fold. Microglial phagocytic capacity may be determined using methods known in the art, for example as described herein. Suitably, the subject may have Parkinson’s disease and dementia. In some embodiments, the subject may have Parkinson’s disease and Parkinson’s dementia. In some embodiments, the subject may have Parkinson’s disease and dementia with Lewy bodies. CELLS In one aspect, the present invention provides a cell comprising the vector of the invention. The cell may be an isolated cell. The cell may be a human cell, suitably an isolated human cell. The cell may be any cell type known in the art. Method of making a cell The vector of the present invention may be introduced into cells using a variety of techniques known in the art, such as transfection, transduction and transformation. Suitably, the vector of the present invention is introduced into the cell by transfection or transduction. In one aspect, the present invention provides a method of making the cell of the invention. The method may comprise introducing the vector of the invention into the cell, for example by transfection or transduction. Suitably, the cell may be from a sample isolated from a subject. The cell may be further The cell of the present invention may be generated by a method comprising the following steps: (i) isolation of a cell-containing sample from a subject or provision of a cell- containing sample; and (ii) transduction or transfection of the cell-containing sample with the vector of the invention, to provide a population of engineered cells. The cells may be cultured prior to, or after, introducing the vector of the invention. The steps may be performed in a closed and sterile cell culture system. The skilled person will understand that they can combine all features of the invention disclosed herein without departing from the scope of the invention as disclosed. Preferred features and embodiments of the invention will now be described by way of non- limiting examples. The practice of the present invention will employ, unless otherwise indicated, conventional techniques of chemistry, biochemistry, molecular biology, microbiology and immunology, which are within the capabilities of a person of ordinary skill in the art. Such techniques are explained in the literature. See, for example, Sambrook, J., Fritsch, E.F. and Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory Press; Ausubel, F.M. et al. (1995 and periodic supplements) Current Protocols in Molecular Biology, Ch.9, 13 and 16, John Wiley & Sons; Roe, B., Crabtree, J. and Kahn, A. (1996) DNA Isolation and Sequencing: Essential Techniques, John Wiley & Sons; Polak, J.M. and McGee, J.O’D. (1990) In Situ Hybridization: Principles and Practice, Oxford University Press; Gait, M.J. (1984) Oligonucleotide Synthesis: A Practical Approach, IRL Press; and Lilley, D.M. and Dahlberg, J.E. (1992) Methods in Enzymology: DNA Structures Part A: Synthesis and Physical Analysis of DNA, Academic Press. Each of these general texts is herein incorporated by reference. EXAMPLES EXAMPLE 1 RESULTS IL-10 is efficiently and specifically expresser in microglia cells Our study focused on nigral microglia because they are numerous in the substantia nigra and important in the pathogenesis of Parkinson's disease. We used the miRNA detargeting technique to generate selective transgene expression by adding sequences complementary to mir124, mir338, and mir31 at the 3' LTR (in tandem 4 times repeated), which are expressed in neurons, oligodendrocytes, and astrocytes, respectively (Fig.1a). By preventing transgenic translation in all but the microglia, the most representative cells in the substantia nigra, this method enabled high cell-specific expression of the therapeutic gene. We assessed RNA levels in primary cultures infected with LV-miRtag-GFP to test the efficient and selective production of the green fluorescent protein (GFP) induced by the miRNA detargeting platform. When compared to primary cortical neurons, where the expression was completely suppressed, the results revealed a considerable increase in the level of GFP transcript in primary microglia (Fig. 1b). We assessed the GFP signal in vivo by microinjecting the LV- miRTag-GFP into the substantia nigra of adult mice in order to confirm the specific expression in adult cells. The study of the stained nigral tissue verified that microglia express transgenes at a higher level than other cell types. In comparison, 13% of the GFP-expressing cells co- localized with neurons (NeuN, 1.6%), astrocytes (GFAP, 3%), and oligodendrocytes (Olig2, 12.7%) whereas the remaining 87% co-localized with the microglia marker IBA1 (Fig.1c). After confirming the high level of cell-specific expression, we incorporated the human interleukin- 10 (IL-10) expression sequence into the viral platform. Through intracerebral injection of LV- miRtag-IL10 (hereafter referred to as LV-IL10) into the substantia nigra, the effectiveness of IL-10 expression was examined in vivo. After 5 weeks, the total level of IL-10 protein in the tissue lysate was determined using ELISA. The outcomes showed that the protein was indeed expressed in the tissue at a rate of 0.3 ng per mg of tissue (Fig. 1d). We assessed the extracellular level of IL-10 to demonstrate the molecule's ability to be released from microglia with a sufficient concentration to achieve a therapeutic impact. We subjected LV-IL10 injected mice to unilateral microdialysis probe implantation into the substantia nigra, and the collected dialysate was examined by ELISA for an accurate quantification of the released IL-10 from microglia in vivo. The results demonstrated an average extracellular IL-10 concentration of 70.8 ng / mL, which, taking into account IL-10's 3% probe recovery rate, equates to a concentration of 73 pM. The IL-10 receptor, whose Kd varies from 50 to 200 pM, is the signaling pathway that is sufficiently activated and bound by this concentration (Fig.1e). IL-10 is an effective neuroprotective agent in experimental model of Parkinson's disease (PD) The substantia nigra pars compacta (SNc) of mice was injected with LV-SNCA, a viral vector that overexpresses alpha-synuclein (aS), to develop a model of PD. This led to the buildup of aS aggregates and progressive neurodegeneration, which are PD hallmarks. In contrast to earlier models, the LV-SNCA model employed in this study demonstrates aS aggregates buildup in a variety of cell types, not just neurons. Therefore, mice were divided into two groups: the IL-10 group received bilateral SNc injections of LV-IL10, and the SNCA + IL10 group received an initial injection of LV-IL10 followed by an injection of LV-SNCA three weeks later. Ten weeks following LV-SNCA injection, there was no discernible decline in the number of tyrosine hydroxylase (TH) positive neurons in the SNc of SNCA + IL10 mice, demonstrating that LV-IL10 overexpression produced a prolonged neuroprotective effect. According to this, elevated IL-10 expression may offer neuroprotection against PD. Importantly, IL-10 overexpression on its own had no neurotoxic effects on dopaminergic neurons in the absence of LV-SNCA injection, demonstrating that IL-10 does not cause neurotoxicity. (Fig 2). Overall, the work shows that IL-10 overexpression in microglia can have a neuroprotective impact in an animal model of PD. LV-inducible platform responds to extracellular IFN-gamma by inducing IL-10 transcription We introduced sequences that can be triggered after IFN gamma signaling in order to make the platform (IL-10 with miRNA detargeting) inducible. These gamma-activated sequences (GAS) were effective at inducing the expression of our platform when IFN gamma was present. We design the inducible platform by using four copies of GAS before the Mx1 minimum promoter (Fig. 3a). We assessed the expression of GFP using immunofluorescence to examine the capacity of our inducible platform to respond to various IFN gamma doses. According to the findings, IFN gamma concentration influenced how much GFP was expressed, with higher concentrations of IFN gamma causing a commensurate rise in GFP expression (Fig.3b). After successfully inducing GFP expression, we switched out GFP for IL- 10 and used RT-PCR to assess the cytokine's expression. The findings show that the presence of IFN gamma significantly increased the amounts of IL-10 transcripts, with levels rising in response to increasing concentrations of IFN gamma stimulation (Fig.3c). Finally, our inducible platform demonstrated enhanced production of IL-10 in the presence of IFN gamma and successfully responded to IFN gamma signaling. For the treatment of neurodegenerative illnesses, especially those with an inflammatory component, this platform has the potential to be a therapeutic tool. DISCUSSION In response to IFN gamma signaling, the data described here show the establishment of an inducible platform for the release of IL-10 a strong anti-inflammatory cytokine The success of IL-10 expression and release from microglia was increased through the use of miRNA detargeting, which forms the foundation of this platform. The promoter region of gamma activated sequences (GAS) allowed for the activation of IL-10 production in response to IFN gamma. Given that IFN gamma is known to be released during inflammation and to be able to contribute to persistent neurodegeneration, this trait is very important. By designing a platform that responds to IFN gamma, we can potentially limit this harmful effect and instead promote neuroprotection. Our findings show that IL-10 expression in our inducible platform can be tuned by IFN gamma concentration, with greater levels of IFN gamma leading to enhanced IL-10 expression. The dynamic response to IFN gamma allows us to precisely control the expression of IL-10 to correspond to the degree of inflammation in a particular situation. Contrary to constitutive expression, the adoption of an inducible platform for IL-10 expression provides a number of potential benefits. In the case of neurodegenerative illnesses, where inflammation is a significant contributor to disease development, the adoption of an inducible platform, for instance, enables the tailored expression of IL-10 in response to certain stimuli. In conclusion, the outcomes shown here demonstrate that an inducible platform for the expression of IL-10 in response to IFN gamma signaling has been successfully developed. In the setting of neurodegenerative illnesses, where inflammation is a significant contributor to disease development, this platform has a number of potential advantages over constitutive expression. METHODS Viral vector and lentivirus production The mirTAG and IL-10 sequences have been inserted in a third-generation lentiviral backbone, downstream of the GAS and Mx1 minimal promoter. MirTAG is made up of three sequences that are repeated four times and are each complementary to miRNAs 124, 338, and 31. Green fluorescent protein (GFP) was initially cloned along with the mirTAG sequence as a reporter to evaluate the expression specificity. The human IL-10 sequence was then inserted after the GFP fragment had been broken up by enzymatic digestion. Lentiviral particles that were VSVg-coated and replication-incompetent were packaged in 293T cells. The day before the infection, 7.5 million 293T cells were plated in a petri dish with a 150mm diameter. The traditional CaCl2 transfection method was used. To concentrate the virus, the medium was collected after 30 hours, filtered (0.44 m cellulose acetate), and centrifuged for 2 hours at 50,000 g. Animals Wild type mice were purchased from Jackson Laboratories and housed in the San Raffaele Hospital animal Facility. They were given free access to food and water while being raised in an environment with a 12 hour dark-light cycle, controlled temperature (25°C), and relative humidity (50–60%). As required by European Commission Council Directive 2010 / 63 / EU, all experiments were carried out in accordance with protocols that had been approved by the Institutional Animal Care and Use Committee (IACUC 1142, Ospedale San Raffaele, Milan, Italy). Surgery After isoflurane anesthesia, the surgical procedure was carried out and throughout the procedure the oxygen and isoflurane levels were adjusted based on the health of the mouse. The lentiviral vectors were administered bilaterally at the angles of AP = 2.9, L = 1.2, and DV = 4.4 from the skull into the substantia nigra pars compacta (SNc).1,5 ul were injected at a flow rate of 0.25 uL per minute. All the lentiviruses were used at a concentration of 1 x 109VP / ml. Mice were sacrificed after 5 or 10 weeks following a specific protocol depending on the type of the analysis. Following the previously mentioned SNc coordinates, the microdialysis probe was inserted following the lentiviral injection. Sutures and a coating of quickly setting cement were used to secure the probe in place. Perfusion fluid CNS (NaCl 147 mmol / L, KCl 2.7 mmol / L, CaCl21,2 mmol / L, MgCl20,85 mmol / L) implemented with 2% bovine serum albumine (BSA) was used to perfuse the probes during the procedure. Microdialysis The microdialysis probe with a 55 kDA cutoff was implanted 4 weeks after the lentivirus injection. Both surgical techniques were as previously described. The probes were perfused with Perfusion fluid CNS at a flow rate of 1 l / min a day after they were implanted. Samples were taken every 50 minutes after a 15-minute rinse and immediately frozen with dry ice.7-8 hours were spent collecting samples. Animal sacrifices were used to confirm histologically that the probes had been positioned correctly at the conclusion of the experiment. Primary cell culture P2 C57BL mice were dissected, and cortices were collected to create a microglia primary culture. The tissue was first incubated at 37°C for 30 minutes in a solution containing 0.05% Trypsin EDTA (Merck) and 100 g / ml DNAse I (Roche), after which the cells were mechanically separated into a suspension and put through a 40 M strainer. The cells were then resuspended NEAA, and 1x Sodium Pyruvate; all from Merck) and plated in T-75 Matrigel GFR (Growth Factor Reduced, Corning) coated flasks (one flask every two pups). The flasks were incubated for approximately 7 days at 37°C with 5% CO2. Flasks were shaken at 400 rpm for four hours at 37°C to separate microglia from the underlying astrocyte layer. Microglia-containing medium was gathered, counted, and seeded in 24-well plates (about 400.000 cells per well). Cells were infected with the desired lentivirus in 1 l / well the following day. Immunostaining Brains from mice were collected and post-fixed the following day after being perfused with freshly prepared 4% PFA in PBS. Brains were successively immersed in a 20% sucrose cryoprotective solution, quickly frozen, and then cut into 50 m slices with a cryostat. Free- floating slices were permeableized for 20 minutes with 2% Triton and 10 minutes with 3% H2O2and 10% CH3OH PBS solution for the immunofluorescence analysis. Slices were incubated for an hour with a solution of 3% BSA and 0.3% Tween after three washes to saturate the atypical sites. Slices were then incubated with the target primary antibody in a diluted blocking solution (1% BSA) overnight at 4°C. Then, slices were incubated with the appropriate secondary antibody for one hour in the dark the following day, after which they were mounted for imaging. Slices were incubated with a biotinylated secondary antibody for the immunohistochemical analysis after being incubated with the primary antibody overnight. The slices were then successively coupled with avidin / biotinylated enzyme complex and revealed with the DAB solution (Vector Laboratories). Stereological count Five 50 m thick SN slices were collected every 200 m for the entire series of SN slices used for each mouse in order to mark the TH positive cells using an immunohistochemical reaction. The Leica DM400B motorized microscope with Stereo Investigator software (MBF Bioscience) was used to count the cells at a 40x magnification. The total number of TH positive cells was then calculated using the optical fractionator stereological probe. Real-Time PCR TRI reagent (Merck) was used to extract total RNA from cells in accordance with the manufacturer's instructions. The ImProm-II Reverse Transcription System from Promega was then used to reverse-transcribe RNA into cDNA. Titan HotTaq EvaGreen qPCR Mix (BioAtlas), custom-designed oligos, and Real Time PCR were used in the experiment. Results were reported as the 2−ΔCt after expression levels were normalized with respect to 18S expression. Both the dialysate and the nigrostriatal tissue were tested for the presence of human IL10 using the ELISA method. On mice injected with LV mirTAG-IL10 or LV Mock, the microdialysis was carried out as previously described, and the samples obtained were stored at -80°C until needed. Mice that had received injections of LV mirTAG-IL10 or LV Mock were then perfused with saline solution to collect tissue samples. The brains were then immediately removed and immediately cut using an acrylic brain matrix (coronal, 1mm) to collect only the SN. The fresh tissue was centrifuged after being mechanically lysed in C+ medium using cOmplete-EDTA free. Before use, the supernatant was collected and kept at -80°C. Using purified and biotinylated antibody pairs, the samples thus obtained were used to perform a standard sandwich ELISA (Becton Dickinson, CA, USA). Blocking Buffer (PBS with 2% BSA) was used to dilute rhIL-10 (R&D Systems, MN, USA) to the manufacturer's recommended concentration. The detection threshold was 15 pg / ml. The weight of the tissue that was collected was used to normalize the tissue sample results. EXAMPLE 2 RESULTS IL-10 enhanced phagocytosis efficiently reduces αSYN aggregate burden in SNpc To understand whether the mechanisms underlying the neuroprotective effect exerted by IL- 10 relies on the boosted phagocytic activity of microglia, we performed in vitro and in vivo assays to discriminate the phagocytic capacity of microglial cells in our different mouse groups. First, we performed immunostainings for CD68, a lysosomal associated protein whose levels are associated with phagosome / lysosome activity. CD68+ intracellular puncta were markedly increased in IBA1+ microglia in both IL10 and SNCAWT+ IL10 animals (Fig.4A, B). CD68+ cells were also significantly increased in size and co-localized with the pS129αSYN+ signal in SNCAWT+ IL10 mice (Fig.4A, C), highlighting the recruitment of αSYN aggregates into the phagosome / lysosome compartment. Next, pS129αSYN+ aggregates were quantified in the SNpc tissue of the different animal groups. pS129αSYN+ deposits were significantly reduced in SNCAWT+ IL10 respect to SNCAWTmice (Fig. 4D, E). Similarly, proteinase K- resistant human αSYN aggregated forms were significantly decreased in both SNpr and SNpc tissue of SNCAWT+ IL10 compared to SNCAWTmice (Fig.4F-H). To determine whether the decreased αSYN aggregates in the brain tissue of SNCAWT+ IL10 mice relied on the IL10- dependent enhanced microglial phagocytic activity, we performed in vitro phagocytosis assays. Primary microglial cell cultures were infected with the same LVs used in the mice for a direct comparison (Mock, IL10, SNCAWTand SNCAWT+ IL10) or seeded with pre-formed fluorescent αSYN fibrils (Fluor488-PFFs) The αSYN Fluor488-PFFs signal internalized by microglial cells significantly increased (measured as the area occupied by Fluor488-PFFs within the cell) in SNCAWT+ IL10 compared to Mock and SNCAWTanimals (Fig.5A, C). As expected, there was a significant decrease in the phagocytosed αSYN PFFs in SNCAWTcompared to Mock microglia (Fig.5A, C). As it is known that αSYN and its oligomeric forms can also enter cells through passive diffusion mechanisms, we repeated the phagocytosis assay employing this time purified striatal synaptosomes loaded with the pH-dependent fluorescent sensor pHrodo. We detected a significant decrease of internalized material considering both the signal intensity and the number of fluorescent particles in SNCAWTmicroglia, which was completely restored following IL-10 treatment (Fig.5B, D, E). Collectively, these results provide consistent evidence that IL-10 enhanced microglial phagocytic capacity, enabling a significant clearance of αSYN aggregates in the SNpc tissue. METHODS Phagocytosis assays Primary microglia cultures were submitted to different phagocytosis assays. In one assay, microglia were seeded with fluorescent preformed fibrils of αSYN (Fluo488-PFFs) at a concentration of 2.3 µM. In the second assay, microglia were exposed to pHrodo Red SE (Thermo Fischer) labelled-synaptosomes preparation. Labelled-synaptosomes were obtained from isolated wild type adult mouse striata. The tissue was homogenized in Syn-PER reagent (Thermo Fisher) using a glass Dounce homogenizer with 4 ml of Syn-PER reagent. The homogenate was transferred in a 15 ml falcon and centrifuged 1200 x g, 10 min at 4°C. The resulting supernatant was collected and centrifuged at 15,000 x g for 20 min at 4°C.The pellet containing the purified synaptosome fraction was weighted for subsequent treatments. pHrodo was reconstituted in 150 ul DMSO (Merck) and added to synaptosomes resuspended in pH 9 0.1M sodium carbonate buffer (Merck) at a final concentration of 200mg / ml. Synaptosomes were incubated for 2h on the shaker at 50 rpm in the dark and then washed two times with PBS. Labelled synaptosomes were added to cells at a 0,5 mg / cm2concentration and incubated for 3h at 37°C 5% CO2. Microglia was then washed four times with PBS and fixed with 4% PFA for the imaging. All publications mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the disclosed vectors, cells, compositions, uses and methods of the invention will be apparent to the skilled person without departing from the scope and spirit of the invention. Although the invention has been disclosed in connection with specific preferred embodiments it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the disclosed modes for carrying out the invention, which are obvious to the skilled person are intended to be within the scope of the following claims.

Claims

CLAIMS 1. A vector for central nervous system (CNS)-specific expression, wherein the vector comprises a transgene encoding interleukin 10 (IL-10), and wherein the transgene is operably linked to one or more expression control sequence.

2. The vector of claim 1, wherein the one or more expression control sequence comprises one or more miRNA target sequence, wherein the one or more miRNA target sequence suppresses expression in cells other than microglia.

3. The vector of claim 1 or 2, wherein the one or more expression control sequence comprises at least one miR-124 target sequence, and / or at least one miR-338-3p target sequence, and / or at least one miR-31 target sequence.

4. The vector of claim 3, wherein: (a) the miR-124 target sequence comprises or consists of a nucleotide sequence that has at least 90% sequence identity to SEQ ID NO: 1; (b) the miR-338-3p target sequence comprises or consists of a nucleotide sequence that has at least 90% sequence identity to SEQ ID NO: 2; and / or (c) the miR-31 target sequence comprises or consists of a nucleotide sequence that has at least 90% sequence identity to SEQ ID NO:

3.

5. The vector of any preceding claim, wherein the vector further comprises a promoter operably linked to the transgene.

6. The vector of claim 5, wherein the promoter comprises or consists of a sequence selected from the group consisting of: (a) a nucleotide sequence that has at least 70% sequence identity to SEQ ID NO: 5 or 6; and (b) the nucleotide sequence of SEQ ID NO: 5 or 6.

7. The vector of claim 1, wherein the vector is for astrocyte-specific expression.

8. The vector of claim 1 or 7, wherein the vector further comprises a promoter comprising or consisting of a sequence selected from the group consisting of:(a) a nucleotide sequence that has at least 70% sequence identity to SEQ ID NO: 34; and (b) the nucleotide sequence of SEQ ID NO:

34.

9. The vector of any preceding claim, wherein the vector further comprises one or more gamma activated sequence (GAS) operably linked to the transgene.

10. The vector of claim 9, wherein the GAS comprises or consists of a sequence selected from the group consisting of: (a) a nucleotide sequence that has at least 90% sequence identity to SEQ ID NO: 7; and (b) the nucleotide sequence of SEQ ID NO:

7.

11. The vector of any preceding claim, wherein the transgene encoding IL-10 comprises or consists of a sequence selected from the group consisting of: (a) a nucleotide sequence encoding an amino acid sequence that has at least 70% sequence identity to SEQ ID NO: 8; (b) a nucleotide sequence that has at least 70% sequence identity to SEQ ID NO: 9; and (c) the nucleotide sequence of SEQ ID NO:

9.

12. The vector of any preceding claim, wherein the vector is a retroviral, lentiviral, AAV or adenoviral vector.

13. A cell comprising the vector of any preceding claim.

14. A pharmaceutical composition comprising the vector or cell of any preceding claim and a pharmaceutically-acceptable carrier, diluent or excipient.

15. The vector, cell or pharmaceutical composition of any preceding claim for use in therapy.

16. The vector, cell or pharmaceutical composition of any one of claims 1-14 for use in treating or preventing Parkinson’s disease.

17. The vector, cell or pharmaceutical composition for use according to claim 15 or 16, wherein the vector, cell or pharmaceutical composition is used in combination with dopamine replacement therapy (DRT).

Citation Information

Patent Citations

  • Retroviral vectors

    WO1998017815A1

  • Anti-viral vectors

    WO1999041397A1

  • Codon optimisation for expression in retrovirus packaging cells

    WO2001079518A2

  • Methods for treating neurodegenerative disorders

    US20060073119A1

  • Pharmaceutical composition including il-10-expressing neural stem cells for treating central nervous system disease or injury and treatment method using the same

    US20180333437A1